Process for preparing cyclo-glycyl-l-2-allylproline

A scalable cyclisation reaction using base reagents addresses the inefficiencies of the existing cG-2-AllylP synthesis, achieving higher yields and purity for large-scale production of bicyclic glycine-proline compounds.

WO2026232202A1PCT designated stage Publication Date: 2026-11-12NEUREN PHARMACEUTICALS LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2026/050463
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The existing process for preparing cyclo-glycyl-L-2-allylproline (cG-2-AllylP) is inefficient and not scalable for clinical investigation and manufacture due to low yields and the formation of difficult-to-isolate salts, making large-scale production challenging.

Method used

A scalable process involving a cyclisation reaction of a compound of Formula 2 in the presence of a base reagent, such as ammonia or metal alkoxides, to form bicyclic glycine-proline compounds like cG-2-AllylP, with improved yields and purity by minimizing the formation of impurities.

Benefits of technology

The new process achieves higher yields and purity, enabling safe and efficient large-scale production of cG-2-AllylP, suitable for clinical development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000001_0001
    Figure IMGF000001_0001
  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
Patent Text Reader

Abstract

The present disclosure provides a process for the synthesis of a bicyclic glycine-proline compound, specifically cyclo-glycyl-L-2-allylproline (cG-2-AllylP). The present disclosure also relates to compounds prepared by the processes and the use of such compounds to prepare compositions and to treat disorders. In particular, there is also provided herein compositions comprising a bicyclic glycine-proline compound and, if present, defined impurities at minimal levels.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PROCESS FOR PREPARING CYCLO-GLYCYL-L-2-ALLYLPROLINE

[0002] Field

[0003] The present disclosure generally relates to a process for the synthesis of a bicyclic glycine-proline compound, and particularly cyclo-glycyl-L-2-allylproline (cG-2-AllylP). The present disclosure also relates to compounds prepared by the processes and the use of such compounds to prepare compositions and to treat disorders.

[0004] Background

[0005] Cyclo-glycyl-L-2-allylproline, also known as cyclic G-2-AllylP and cG-2-AllylP, is a synthetic analogue of the neurotrophic peptide, cyclic glycine proline (cGP). cGP occurs naturally in the brain and is believed to be associated with a series of neurophysiological effects, although its precise mechanism of action remains unknown.

[0006]

[0007] cG-2-AllylP

[0008] cG-2-AllylP has been investigated as the clinical candidate, NNZ-2591, and has demonstrated efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X Syndrome, memory impairment, multiple sclerosis, Phelan-McDermid Syndrome, Pitt Hopkins Syndrome, Angelman Syndrome and Prader-Willi Syndrome.

[0009] To date, the reported process for preparing cG-2-AllylP comes from the international PCT publication W02005 / 023815, and is shown in Scheme 1, below. According to the reported process, oxazolidinone 2 can be synthesised by reacting chloral with (S)-proline. This oxazolidinone 2 is then deprotonated using lithium diisopropylamide (LDA), followed by reaction with allyl bromide to produce allyl-oxazolidinone 3. Reaction of the allyl-oxazolidinone 3 with anhydrous hydrogen chloride (generated by reaction of acetyl chloride with methanol) forms the ring-opened monocyclic ester 4 as the hydrochloride salt, which is then reacted with N-boc-protected glycine 5 to form the dipeptide 6. An N-terminus deprotection of dipeptide 6 is provided using an acid, followed by a cyclisation reaction usinga weak base for elimination of the methoxy group of the methyl ester, to obtain the bicyclic glycine-proline compound 1, cG-2-AllylP.

[0010]

[0011] 6 1 Scheme 1. Reagents, conditions, and yields: (i) LDA, THF, -78 °C, allyl bromide, -78 °C -30 °C, N2, 4 h (60%); (ii) acetyl chloride, CH3OH, reflux, N2, 24 h (63%); (iii) Et3N, BoPCl, CH2Cl2, RT, N2, 19.5 h (45%); (iv) TFA, CH2Cl2, 1 h, then Et3N, CH2Cl2, 23 h (37%).

[0012] A drawback to the reported process is the inability to efficiently scale this chemistry to the quantities that are required for clinical investigation and manufacture for clinical development.

[0013] This is highlighted in particular by the yields of each reaction step, which combine to provide a total yield over the four reaction steps of approximately 6%. This is, in part, due to purification being required at each step, typically in the form of flash chromatography. Such flash chromatography is not viable in the purification of large-scale quantities. It was also found that the use of TFA (trifluoroacetic acid) and Et3N (triethylamine) for the cyclisation step can result in a mixture of salts being formed from which it is difficult to isolate NNZ-2591 as a free compound.

[0014] Accordingly, there remains a need for an efficient and safe scalable process for preparing cG-2-AllylP and its analogues in good yields and high purity.Summary

[0015] The subject matter of the present disclosure is predicated in part on the development of an efficient and safe scalable process for preparing bicyclic glycine-proline compounds, including cG-2-AllylP.

[0016] It will be appreciated that other aspects, embodiments, and examples of the compounds, pharmaceutical compositions, methods, or uses, are further described herein.

[0017] In one aspect, there is provided a process for preparing a bicyclic glycine-proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0018]

[0019] Formula 2 Formula 1;

[0020] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; and X1is a halogen.

[0021] In some embodiments, the cyclisation reaction is performed in the presence of a base reagent.

[0022] In some embodiments, the process further comprises preparing a compound of Formula 2 via an N-acy lation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0023]

[0024] Formula 3 Formula 4 Formula 2;

[0025] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; X1is a halogen; and X2is a halogen.In a further aspect, there is provided a process for preparing a compound of Formula 2, comprising an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0026]

[0027] Formula 3 Formula 4 Formula 2;

[0028] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; X1is a halogen; and X2is a halogen.

[0029] In some embodiments, the process further comprises reacting a compound of Formula 2 to form the compound of Formula 1:

[0030]

[0031] Formula 2 Formula 1;

[0032] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; and X1is a halogen.

[0033] In some embodiments, the bicyclic glycine-proline compound of Formula 1 is a bicyclic glycine-proline compound of Formula la(R):

[0034]

[0035] In a further aspect, there is provided a bicyclic glycine-proline compound of Formula1:

[0036]

[0037] Formula 1;

[0038] wherein R1is as described herein, prepared by the process as described herein.

[0039] In a further aspect, there is provided a bicyclic glycine-proline compound of Formula la:

[0040]

[0041] Formula la;

[0042] prepared by the process as described herein.

[0043] In other aspects or embodiments, there is provided a compound of Formula 2, Formula 3, Formula 5, or Formula 6, prepared from any one or more processes as described by the above aspects, or any embodiments or examples thereof as described herein.

[0044] In other aspects or embodiments, there is provided a composition comprising a compound of any one of Formula 1, Formula 2, Formula 3, Formula 5, or Formula 6, or any embodiments or examples thereof as described herein. The compounds in the compositions can be provided in high purity and / or with low amounts of one or more impurities (e.g. by-product and / or reagent) according to any embodiments or examples thereof as described herein. In other aspects there may be pharmaceutical compositions comprising the compounds or compositions thereof and one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0045] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula la:

[0046]

[0047] Formula la;wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, or 0.0001.

[0048] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0049]

[0050] Formula la;

[0051] wherein a compound of Formula 2:

[0052]

[0053] Formula 2;

[0054] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OC1-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; and X1is a halogen.

[0055] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0056]

[0057] Formula la;

[0058] wherein a compound of Formula 2a':

[0059]

[0060] Formula 2a';

[0061] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein X1is a halogen.

[0062] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0063]

[0064] Formula la;

[0065] wherein Impurity g:

[0066]

[0067] Impurity g;

[0068] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0069] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0070]

[0071] Formula la;

[0072] wherein Impurity h:

[0073]

[0074] Impurity h;

[0075] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0076] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0077]

[0078] Formula la;

[0079] wherein Impurity i:

[0080]

[0081] Impurity i;

[0082] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0083] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0084]

[0085] Formula la;

[0086] wherein Impurity j:

[0087]

[0088] Impurity j;

[0089] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0090] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0091]

[0092] Formula la;

[0093] wherein Impurity k:

[0094]

[0095] Impurity k;

[0096] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0097] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R):

[0098]

[0099] Formula la( / ?);

[0100] wherein Impurity la(S):

[0101]

[0102] Impurity la(S);

[0103] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0104] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0105]

[0106] Formula la;

[0107] wherein Impurity a:

[0108]

[0109] Impurity a;

[0110] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0111] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0112]

[0113] Formula la;

[0114] wherein Impurity b:

[0115]

[0116] Impurity b;

[0117] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0118] In some embodiments, there is provided a composition comprising a compound of Formula la:

[0119]

[0120] Formula la;

[0121] wherein Impurity c:

[0122]

[0123] Impurity c;

[0124] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0125] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0126]

[0127] Formula la;

[0128] wherein Impurity d:

[0129]

[0130] Impurity d;

[0131] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0132] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention as described herein.

[0133] Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of matter.

[0134] Detailed Description

[0135] General Definitions

[0136] Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, biochemistry, medicinal chemistry, microbiology and the like).

[0137] As used herein, the term “and / or”, e.g., “X and / or Y”, shall be understood to mean either " X and Y" or " X or Y" and shall be taken to provide explicit support for both meanings or for either meaning, e.g., A and / or B includes the options i) A, ii) B, or iii) A and B.As used herein, the term “about”, unless stated to the contrary, refers to + / - 20%, typically + / - 10%, typically + / - 5%, of the designated value.

[0138] As used herein, the terms “a”, “an”, and “the” include both singular and plural aspects, unless the context clearly indicates otherwise.

[0139] It is to be appreciated that certain features that are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination.

[0140] Throughout the present specification, various aspects and components of the invention can be presented in a range format. The range format is included for convenience and should not be interpreted as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range, unless specifically indicated. For example, description of a range such as from 1 to 5 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 5, from 3 to 5 etc., as well as individual and partial numbers within the recited range, for example, 1, 2, 3, 4, 5, 5.5 and 6, unless where integers are required or implicit from context. This applies regardless of the breadth of the disclosed range. Where specific values are required, these will be indicated in the specification.

[0141] Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0142] It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art in the United States, Australia, or in any other country.

[0143] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, willprevail. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0144] Salts may be formed in the case of embodiments of the compounds of Formulae 1 to 7, which contain a suitable acidic or basic group. Suitable salts of the compounds of Formulae 1 to 7 include those formed with organic or inorganic acids or bases. Accordingly, it will be appreciated, that in referring to a compound by its formula (i.e., Formula 1), reference is made to both the free-base / free-acid compound, and the corresponding salt thereof.

[0145] As used herein, the phrase “pharmaceutically acceptable salt” or a like term refers to pharmaceutically acceptable organic or inorganic salts. It will be appreciated that any reference to “salt” herein can include “pharmaceutically acceptable salts”. Exemplary acid addition salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1 ' -methylene-bis-(2-hydroxy-3-naphthoate)) salts. Exemplary base addition salts include, but are not limited to, ammonium salts, alkali metal salts, for example those of potassium and sodium, alkaline earth metal salts, for example those of calcium and magnesium, and salts with organic bases, for example dicyclohexylamine, N-methyl-D-glucamine, morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl -propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and / or one or more counterions. It will also be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present disclosure since these may be useful as intermediates in the preparation of pharmaceutically acceptable salts or may be useful during storage or transport.

[0146] Those skilled in the art of organic and / or medicinal chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from whichthey are precipitated or crystallized. These complexes are known as “solvates”. For example, a complex with water is known as a “hydrate”. As used herein, the phrase “pharmaceutically acceptable solvate” or “solvate” refer to an association of one or more solvent molecules and a compound of the present disclosure. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropyl alcohol, ethanol, methanol, dimethylsulfoxide, ethyl acetate, isopropyl acetate, acetic acid, and ethanolamine. It will be understood that the present disclosure encompasses solvated forms, including hydrates, of the compounds of Formula 1 and salts thereof.

[0147] The compounds of the present disclosure may contain chiral (asymmetric) centers or the molecule as a whole may be chiral. The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are within the scope of the present disclosure.

[0148] As used herein, the term “stereoisomer” refers to compounds having the same molecular formula and sequence of bonded atoms (i.e., atom connectivity), though differ in the three-dimensional orientations of their atoms in space. As used herein, the term “enantiomers” refers to two compounds that are stereoisomers in that they are non- superimposable mirror images of one another. Relevant stereocenters may be denoted with (R)- or ()- configuration.

[0149] Those skilled in the art of organic and / or medicinal chemistry will appreciate that the compounds of Formula 1 and salts thereof may be present in an amorphous form or in a crystalline form. It will be understood that the present disclosure encompasses all forms and polymorphs of the compounds of Formula 1 and salts thereof.

[0150] Implicit hydrogen atoms (such as the hydrogen atoms present on the pyrrole ring, etc.) are omitted from the formulae for clarity, but would be understood by the skilled person to be present.

[0151] As used herein, the term “alkyl” encompasses both straight-chain (i.e., linear) and branched-chain hydrocarbon groups. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, i-butyl, sec-butyl, pentyl, and hexyl groups. In one example, the alkyl group is of one to eight carbon atoms (i.e. C1-8alkyl). In one example, the alkyl group is of one to six carbon atoms (i.e. C1-6alkyl).

[0152] As used herein, the term “aryl” encompasses aromatic, hydrocarbon ring substituents. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. In one example, the aryl group is of three to eight carbon atoms (i.e. C3-8aryl). In one example, the aryl group is of six carbon atoms (i.e. C6aryl, phenyl).As used herein, the term “substantially free”, particularly when used in relation to a composition comprising, for example, a predominant compound (by weight) and an impurity, refers to that impurity being present in the composition in a trace amount, for example, less than about 0.5, less than about 0.1, less than about 0.01, or less than about 0.001 weight % of the amount of the predominant compound in the composition. In some embodiments, “substantially free” refers to a composition comprising an impurity in which the impurity is present in such a low amount that it is barely detectable in the composition. It will be appreciated that a composition that is “substantially free” of an impurity, in some embodiments, describes a composition in which the impurity does not affects the desired properties or activity of the predominant compound in that composition. In one example, “substantially free” of an impurity means the impurity is present in an amount of less than about 0.01 weight % of the amount of the predominant compound in the composition. In one example, “substantially free” of an impurity means the impurity is present in an amount of less than about 0.001 weight % of the amount of the predominant compound in the composition.

[0153] All documents cited or referenced herein, and all documents cited or referenced in herein cited documents, together with any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference in their entirety.

[0154] Process for Preparing a Compound of Formula 1

[0155] The subject matter of the present disclosure is predicated in part on the discovery of an efficient, safe, and scalable process for preparing a bicyclic glycine-proline compound of Formula 1(R), including a compound of Formula 1a(R) and Formula 1b(R). Scheme 2, below, provides an example of an efficient, safe, and scalable process for preparing a bicyclic glycineproline compound of Formula 1(R) (Formula 1a(R): cG-2-AllylP).

[0156]

[0157] Scheme 2. Exemplary process for the preparation of a bicyclic glycine -proline compound of Formula 1 (R), including Formula 1a(R) and Formula 1b(R) (Formula 1a(R): cG-2-AllylP).

[0158] The above process is described further below in relation to each of the steps of the process. Each step may provide its own independent process aspect, embodiment, or example for preparing an intermediate or compound per se, or may provide a further embodiment or example to another process aspect or embodiment as described herein. Each intermediate or prepared compound of each step may also provide its own independent aspect, embodiment, or example, in relation to compounds, compositions, and / or processes thereof.

[0159] Synthesis of a Compound of Formula 1 - Cyclisation Reaction

[0160] The present disclosure provides a process for preparing a bicyclic glycine-proline compound of Formula 1:

[0161]

[0162] Formula 1.

[0163] In one example, the bicyclic glycine-proline compound of Formula 1 is the bicyclic glycine-proline compound of Formula la:

[0164]

[0165] Formula la.

[0166] In one example, the bicyclic glycine -proline compound of Formula 1 is the bicyclic glycine-proline compound of Formula la(R):

[0167]

[0168] Formula 1a().

[0169] In some embodiments, the process for preparing a bicyclic -proline compound of Formula 1 comprises a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0170]

[0171] Formula 2 Formula 1;

[0172] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; and X1is a halogen. Herein, this process is referred to as the “cyclisation reaction”.

[0173] In some embodiments, R1is selected from the group consisting of -H, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl. In one example, R1is -H. In some embodiments, R1is -Ci-6alkyl. In one example R1is -Cialkyl (i.e., -CH3). In one example, R1is -Cialkyl. In one example, R1is -Csalkyl. In one example, R1is -C4alkyl. In one example, R1is -Csalkyl. In one example, R1is -Cealkyl. In some embodiments, R1is -Ci-6alkyl-C3-8aryl. In one example, R1is -Cialkyl-C6aryl (i.e., -benzyl). In some embodiments, R1is -C3-8aryl. In some embodiments, R1is -C(O)OCi-6alkyl. In one example, R1is -C(O)OC4alkyl (e.g., boc group). In some embodiments, R1is -C(O)Ci-6alkyl. In some embodiments, R1is -Ci-6alkyl-C(O)-Ci-6alkyl. Where a -C3-8aryl is present, as in when R1is -Ci-6alkyl-C3-8aryl or -C3-8aryl, the -C3-8aryl may optionally be further substituted, at any relevant carbon, with -OCi-4alkyl. In some embodiments, R1is -Ci-ealkyl-C3-8aryl, wherein the C3-8aryl is further substituted with -OC1-4alkyl. Similarly, in some embodiments, R1is -C3-8aryl, wherein the C3-8aryl is further substituted with -OCi-4alkyl. In one example, R1is -Cialkyl-C6aryl, wherein the C6aryl is further substituted with -OCialkyl (i.e., R1is para-methoxybenzyl, PMB).

[0174] In some embodiments, X1is a halogen. In some embodiments, X1is a halogen selected from the group consisting of fluorine, chlorine, bromine, and iodine. In some embodiments, X1is selected from the group consisting of chlorine and bromine. In one example, X1is chlorine. In one example, X1is bromine. In one example, X1is fluorine. In one example, X1is iodine In some embodiments, the process for preparing a bicyclic-proline compound of Formula la comprises a cyclisation reaction of a compound of Formula 2a' to form the compound of Formula la:

[0175]

[0176] Formula 2a' Formula la;

[0177] wherein X1is a halogen.

[0178] In some embodiments, the process for preparing a bicyclic-proline compound of Formula la(R) comprises a cyclisation reaction of a compound of Formula 2a'(R) to form the compound of Formula la(R):

[0179]

[0180] Formula 2a'( / ?) Formula la( / ?);

[0181] wherein X1is a halogen.

[0182] In some embodiments, the compound of Formula 2 is selected from the group consisting of:

[0183]

[0184] Formula 2a; and Formula 2b.

[0185] In one example, the compound of Formula 2 is a compound of Formula 2a:

[0186]

[0187] Formula 2a.

[0188] In one example, the compound of Formula 2 is a compound of Formula 2b:

[0189]

[0190] Formula 2b.

[0191] In one example, the compound of Formula 2 is a compound of Formula 2a(7?):

[0192]

[0193] In one example, the compound of Formula 2 is a compound of Formula 2b(7?):

[0194]

[0195] In some embodiments, there is provided a process for preparing a bicyclic-proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 in the presence of a base reagent to form the compound of Formula 1:

[0196]

[0197] Formula 2 Formula 1;

[0198] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(0)0Ci-6alkyl, -C(0)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -0Ci-4alkyl; and X1is a halogen.

[0199] In some embodiments, the process for preparing a bicyclic-proline compound of Formula la comprises a cyclisation reaction of a compound of Formula 2a' in the presence of an ammonia reagent to form the compound of Formula la:

[0200]

[0201] Formula 2a' Formula la;

[0202] wherein X1is a halogen.

[0203] In some embodiments, the process for preparing a bicyclic-proline compound of Formula la(R) comprises a cyclisation reaction of a compound of Formula 2a'(R) in the present of an ammonia reagent to form the compound of Formula la(R):

[0204]

[0205] Formula 2a'( / ?) Formula la( / ?);

[0206] wherein X1is a halogen.

[0207] As used herein, the term “base reagent” refers to a reagent capable of accepting protons (H+) or donating electrons when reacted in situ. In some embodiments, the base reagent isselected from the group consisting of an ammonia reagent, a metal alkoxide, a metal carbonate, a metal phosphate, a metal hydroxide, a metal hydride, a metal amine, a metal silylamide, and a combination thereof. In one example, the base reagent is a metal alkoxide. In one example, the base reagent is a metal carbonate. In one example, the base reagent is a metal phosphate. In one example, the base reagent is a metal hydroxide. In one example, the base reagent is a metal hydride. In one example, the base reagent is a metal amine. In one example, the base reagent is a metal silylamide.

[0208] In some embodiments, the base reagent is selected from the group consisting of sodium methoxide (NaOMe), sodium ethoxide (NaOEt), sodium isopropoxide, sodium tert-butoxide (NaOfBu), sodium bis(trimethylsilyl)amide (NaHMDS), lithium bis(trimethylsilyl)amide (LiHMDS), sodium hydride (NaH), sodium hydroxide (NaOH), potassium hydroxide (KOH), potassium carbonate (K2CO3), sodium carbonate, lithium diisopropylamide (LDA), potassium methoxide (KOMe), potassium ethoxide (KOEt), potassium isopropoxide, potassium tert-butoxide (KOfBu), tripotassium phosphate (K3PO4), and combinations thereof. In some embodiments, the base reagent is selected from the group consisting of potassium hydroxide (KOH), tripotassium phosphate (K3PO4), sodium methoxide (NaOMe), and lithium bis(trimethylsilyl)amide (LiHMDS). In one example, the base reagent is potassium hydroxide (KOH). In one example, the base reagent is tripotassium phosphate (K3PO4). In one example, the base reagent is sodium methoxide (NaOMe). In one example, the base reagent is lithium bis(trimethylsilyl)amide (LiHMDS).

[0209] In some embodiments, the base reagent is an ammonia reagent. As used herein, the term “ammonia reagent” refers to a reagent that provides a source of ammonia in situ during the cyclisation reaction. The ammonia reagent may be any ammonia reagent that provides a source of ammonia in situ during the cyclisation reaction. In some embodiments, the ammonia reagent is selected from the group consisting of ammonia in organic solvent, gaseous ammonia, liquid ammonia (e.g., anhydrous), and sodium amide. In one example, the ammonia reagent is gaseous ammonia. In one example, the ammonia reagent is liquid ammonia. In one example, the ammonia reagent is sodium amide.

[0210] When the ammonia reagent is ammonia in an organic solvent, it will be appreciated that the organic solvent may be any suitable organic solvent. Examples of organic solvents include, but are not limited to, tetrahydrofuran (THF) and dioxane. In one example, the organic solvent is tetrahydrofuran (THF), and the ammonia reagent is ammonia in tetrahydrofuran (THF). In other embodiments, the organic solvent is an alcoholic solvent. When the ammonia reagent is ammonia in alcoholic solvent, it will be appreciated that the alcoholic solvent may be anysuitable alcoholic solvent. In some embodiments, the ammonia reagent is ammonia in an alcoholic solvent selected from the group consisting of ammonia in methanol solvent, ammonia in ethanol solvent, ammonia in isopropanol solvent, and combinations thereof. In some embodiments, the ammonia reagent is ammonia in an alcoholic solvent selected from the group consisting of ammonia in methanol solvent, ammonia in isopropanol solvent, and combinations thereof. In one example, the ammonia reagent is ammonia in methanol solvent. In one example, the ammonia reagent is ammonia in ethanol solvent. In one example, the ammonia reagent is ammonia in isopropanol solvent.

[0211] The ammonia reagent may be provided in the cyclisation reaction at a particular concentration, defined by molality (N, total moles of a solute per kilogram of solvent, or solute concentration in a mass of solution). In some embodiments, the ammonia reagent is provided in a concentration of at least about 0.5 N, 1.0 N, 2.0 N, 3.0 N, 4.0 N, 5.0 N, 6.0 N, 7.0 N, 8.0 N, 9.0 N, or 10 N. In one example, the ammonia reagent is provided in a concentration of greater than about 1.0 N. In one example, the ammonia reagent is provided in a concentration of greater than about 2.0 N. In one example, the ammonia reagent is provided in a concentration of greater than about 4.0 N. In some embodiments, the ammonia reagent is provided in a concentration of less than about 20 N, 10 N, 9.0 N, 8.0 N, or 7.0 N. In some embodiments, the ammonia reagent is provided in a concentration of between about 1.0 N and 10 N, between about 4.0 N and 9.0 N, or between about 6.0 N and 8.0 N. In one example, the ammonia reagent is provided in a concentration of about 7.0 N.

[0212] The ammonia reagent may be provided in the cyclisation reaction at a particular stoichiometric amount. This “stoichiometric amount”, which may also be referred to as a “stoichiometric ratio”, defines the number of moles of the reagent relative to another reagent. The term “molar equivalent” specifically refers to the ratio of moles of one reagent to the moles of another reagent. The ammonia reagent may be provided in the cyclisation reaction in any molar equivalent amount suitable so as to effect the cyclisation reaction. In some embodiments, the ammonia reagent is provided in a molar equivalent amount of ammonia of at least about 5, 10, 15, 16, 17, 18, 19, 20, or 25, relative to the molar amount of the compound of Formula 2. In some embodiments, the ammonia reagent is provided in a molar equivalent amount of ammonia of less than about 40, 35, 30, 25, or 20, relative to the molar amount of the compound of Formula 2. In some embodiments, the ammonia reagent is provided in a molar equivalent amount of ammonia of between about 5 and 40, between about 10 and 30, or between about 15 and 25, relative to the molar amount of the compound of Formula 2. In one example, the ammonia reagent is provided in a molar equivalent amount of ammonia of about 20, relative tothe molar amount of the compound of Formula 2.

[0213] As will be appreciated by the person skilled in the art, the cyclisation reaction will be performed in a suitable solvent. In one example, the cyclisation reaction is performed in the presence of an organic solvent. In some embodiments, the cyclisation reaction is performed in the presence of an organic solvent selected from the group consisting of a chlorinated hydrocarbon solvent, an ether solvent, an organic nitrile solvent, an alcohol solvent, and combinations thereof. In one example, the organic solvent is an organic nitrile solvent. In one example, the organic solvent is an alcohol solvent. In one example, the organic solvent is a chlorinated hydrocarbon solvent. In one example, the organic solvent is an ether solvent. In one example, the organic solvent is a combination of a chlorinated hydrocarbon solvent and an ether solvent.

[0214] Examples of organic nitrile solvents include, but are not limited to, acetonitrile. Accordingly, in one example, the organic solvent is acetonitrile.

[0215] Examples of alcohol solvents include, but are not limited to, methanol, ethanol, and isopropanol. Accordingly, in one example, the organic solvent is methanol. In one example, the organic solvent is ethanol. In one example, the organic solvent is isopropanol.

[0216] Examples of chlorinated hydrocarbon solvents include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, trichloroethylene, and tetrachloroethylene. Accordingly, in one example, the organic solvent is dichloromethane. In one example, the organic solvent is chloroform.

[0217] Examples of ether solvents include, but are not limited to, diethyl ether, tetrahydrofuran, tetrahydropyran, 1,2-dimethoxyethane, methyl tert-butyl ether, 2-methyltetrahydrofuran, and 1,4-dioxane. Accordingly, in one example, the organic solvent is methyl tert-butyl ether. In one example, the organic solvent is tetrahydrofuran. In one example, the organic solvent is 2-methyltetrahydrofuran. In some embodiments, the organic solvent is selected from the group consisting of dichloromethane, methyl tert-butyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, and combinations thereof.

[0218] In some embodiments, the cyclisation reaction is performed at room temperature (i.e., about 20 °C). In one example, the cyclisation reaction is performed at 20 °C. In some other embodiments, the person skilled in the art will appreciate that it may be necessary to apply heat to facilitate the cyclisation reaction. The amount of heat required may depend upon the solvent in which the reaction is performed in, as discussed above. In some embodiments, the cyclisation reaction is performed at least at about 10 °C, about 20 °C, about 30 °C, or about 40 °C. In someembodiments, the cyclisation reaction is performed at less than at about 50 °C, 45 °C, 40 °C, 35 °C, or 30 °C. In some embodiments, the cyclisation reaction is performed at between about 10 °C and 50 °C, between about 20 °C and 40 °C, or between about 25 °C and 35 °C. In one example, the cyclisation reaction is performed at between about 25 °C and 35 °C. In one example, the cyclisation reaction is performed at about 30 °C.

[0219] As would be appreciated by the person skilled in the art, it is possible to monitor the progress of a reaction by measuring the conversion of the one or more reagents to the desired product. This monitoring may occur through any suitable means as would be known to the person skilled in the art, including, for example, TLC (thin layer chromatography) and HPLC (high-performance liquid chromatography). With HPLC, for example, it is necessary to know the retention times of the reagents and products, and from here, the area under each peak can be analysed to calculate the relative amounts of reagents and product, and therefore the percentage conversion of reagents to the desired product. An aliquot of the reaction mixture may be taken at any time point during the reaction and analysed by HPLC. In some embodiments, the cyclisation reaction is monitored by HPLC. In some embodiments, an aliquot of the reaction mixture is taken at about one hour, five hours, 20 hours, and / or four days following commencement of the cyclisation reaction, and analysed by HPLC. In one example, an aliquot of the reaction mixture is taken at about 20 hours following commencement of the cyclisation reaction.

[0220] Accordingly, in some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2 to the compound of Formula 1, when measured at about 20 hours following commencement of the reaction. In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1 and when analysed by HPLC. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2 to the compound of Formula 1, when measured at about 20 hours following commencement of the reaction and when analysed by HPLC.

[0221] Similarly, as would also be appreciated by the person skilled in the art, it is possible to measure the yield of the reaction. As used herein, the term “yield” will be taken to mean the amount of either crude or purified compound obtained from a reaction, measured as a percentage of theoretical yield of the compound in that reaction, as would be understood by theperson skilled in the art. In some embodiments, the cyclisation reaction provides a yield of a compound of Formula 1 of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 2 starting reagent. In some embodiments, the cyclisation reaction provides a yield of a compound of Formula 1 of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 2 starting reagent.

[0222] In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2a' to the compound of Formula la. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2a' to the compound of Formula la, when measured at about 20 hours following commencement of the reaction. In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2a' to the compound of Formula la and when analysed by HPLC. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2a' to the compound of Formula la, when measured at about 20 hours following commencement of the reaction and when analysed by HPLC.

[0223] In some embodiments, the cyclisation reaction provides a yield of a compound of Formula la of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 2a' starting reagent. In some embodiments, the cyclisation reaction provides a yield of a compound of Formula la of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 2a' starting reagent.

[0224] In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2a to the compound of Formula la. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2a to the compound of Formula la, when measured at about 20 hours following commencement of the reaction. In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2a to the compound of Formula la and when analysed by HPLC. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2a to the compound ofFormula la, when measured at about 20 hours following commencement of the reaction and when analysed by HPLC.

[0225] In some embodiments, the cyclisation reaction provides a yield of a compound of Formula la of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 2a starting reagent. In some embodiments, the cyclisation reaction provides a yield of a compound of Formula la of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 2a starting reagent.

[0226] In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2b to the compound of Formula la. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2b to the compound of Formula la, when measured at about 20 hours following commencement of the reaction. In some embodiments, the cyclisation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2b to the compound of Formula la and when analysed by HPLC. In some embodiments, the cyclisation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 2b to the compound of Formula la, when measured at about 20 hours following commencement of the reaction and when analysed by HPLC.

[0227] In some embodiments, the cyclisation reaction provides a yield of a compound of Formula la of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 2b starting reagent. In some embodiments, the cyclisation reaction provides a yield of a compound of Formula la of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 2b starting reagent.

[0228] In some embodiments, the cyclisation reaction provides a compound of Formula 1 in high purity. As would be understood by a skilled person, purity is a measure independent of yield. That is, a compound may have a high purity, albeit a low yield. As used herein, the term “high purity” refers to at least 80% of the ultimately obtained material being the desired compound (e.g., a compound of Formula 1), which may be measured, for example, by HPLC. The purity of a compound may be measured based on the crude reaction mixture, the productisolated from the reaction mixture (i.e., following the reaction work-up), or the purified product (i.e., following chromatography, recrystallization, etc.).

[0229] In some embodiments, the cyclisation reaction provides a compound of Formula 1 in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the cyclisation reaction provides a compound of Formula 1 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 1 in the crude reaction mixture. In some embodiments, the cyclisation reaction provides a compound of Formula 1 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 1 isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the cyclisation reaction provides a compound of Formula 1 following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the cyclisation reaction provides a compound of Formula 1 following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the cyclisation reaction provides a compound of Formula 1 following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity.

[0230] In some embodiments, the cyclisation reaction provides a compound of Formula la in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the cyclisation reaction provides a compound of Formula la in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula la in the crude reaction mixture. In some embodiments, the cyclisation reaction provides a compound of Formula la in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula la isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the cyclisation reaction provides a compound of Formula la following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the cyclisation reaction provides a compound of Formula la following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the cyclisation reaction provides a compound of Formula la following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity.

[0231] In some embodiments, the process for preparing a bicyclic -proline compound of Formula la comprising a cyclisation reaction of a compound of Formula 2a' to form thecompound of Formula la beneficially reduces or avoids the generation of any one or more unwanted by-products, impurities, or residues selected from the group consisting of:

[0232]

[0233] Impurity j; and Impurity k.

[0234] In some embodiments, the process for preparing a bicyclic glycine-proline compound of Formula la(R) comprising a cyclisation reaction of a compound of Formula 2a'(R) to form the compound of Formula la(R) beneficially reduces or avoids the generation of any one or more by-products, impurities, or residues selected from the group consisting of:

[0235]

[0236] Impurity j( / ?); Impurity k(R); and Formula la(S).

[0237] In some embodiments, the cyclisation reaction occurs with a starting material amount of a compound of Formula 2 of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg. In some embodiments, the cyclisation reaction occurs with a starting material amount of a compound of Formula 2a of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg. In some embodiments, the cyclisation reaction occurs with a starting material amount of a compound of Formula 2a' of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg. That is, the cyclisationreaction occurs on at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg scale.

[0238] In some embodiments, the cyclisation reaction further comprises preparing a compound of Formula 2 via an N- acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0239]

[0240] Formula 3 Formula 4 Formula 2;

[0241] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; X1is a halogen; and X2is a halogen. That is, in some embodiments, the cyclisation reaction further comprises the N- acylation reaction, as described herein, to form the compound of Formula 2.

[0242] Synthesis of a Compound of Formula 2 – N-Acylation Reaction

[0243] The present disclosure provides a process for preparing a compound of Formula 2:

[0244]

[0245] Formula 2.

[0246] In one example, the compound of Formula 2 is the compound of Formula 2(7?):

[0247]

[0248] Formula 2(R).

[0249] In one example, the compound of Formula 2 is the compound of Formula 2a'(R):

[0250]

[0251] Formula 2a'( / ?).

[0252] In some embodiments, the process for preparing a compound of Formula 2 comprises an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0253]

[0254] Formula 3 Formula 4 Formula 2;

[0255] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; X1is a halogen; and X2is a halogen. Herein, this process is referred to as the ‘W-acylation reaction”. In some embodiments, the N-acylation reaction occurs under Schotten-Baumann reaction conditions, or a variation thereof.

[0256] In some embodiments, the process for preparing a compound of Formula 2(R) comprises an N-acylation reaction of a compound of Formula 3(R) with a dihalide compound of Formula 4:

[0257]

[0258] Formula 3( / ?) Formula 4 Formula 2( / ?);

[0259] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; X1is a halogen; and X2is a halogen.

[0260] In some embodiments, R1is selected from the group consisting of -H, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl. In one example, R1is -H. In some embodiments, R1is -Ci-6alkyl. In one example R1is -Cialkyl (i.e.,-CH3). In one example, R1is -Cialkyl. In one example, R1is -Csalkyl. In one example, R1is -C4alkyl. In one example, R1is -Csalkyl. In one example, R1is -Cealkyl. In some embodiments, R1is -Ci-6alkyl-C3-8aryl. In one example, R1is -Cialkyl-C6aryl (i.e., -benzyl). In some embodiments, R1is -C3-8aryl. In some embodiments, R1is -C(O)OCi-6alkyl. In one example, R1is -C(O)OC4alkyl (e.g., boc group). In some embodiments, R1is -C(O)Ci-6alkyl. In some embodiments, R1is -Ci-6alkyl-C(O)-Ci-6alkyl. Where a -C3-8aryl is present, as in when R1is -Ci-6alkyl-C3-8aryl or -C3-8aryl, the -C3-8aryl may optionally be further substituted, at any relevant carbon, with -OCi-4alkyl. In some embodiments, R1is -Ci-ealkyl-C3-8aryl, wherein the C3-8aryl is further substituted with -OCi alkyl. Similarly, in some embodiments, R1is -C3-8aryl, wherein the C3-8aryl is further substituted with -OCi-4alkyl. In one example, R1is -Cialkyl-C6aryl, wherein the C6aryl is further substituted with -OCialkyl (i.e., R1is para-methoxybenzyl, PMB).

[0261] In some embodiments, X1is a halogen. In some embodiments, X1is a halogen selected from the group consisting of fluorine, chlorine, bromine, and iodine. In some embodiments, X1is selected from the group consisting of chlorine and bromine. In one example, X1is chlorine. In one example, X1is bromine. In one example, X1is fluorine. In one example, X1is iodine.

[0262] In some embodiments, X2is a halogen. In some embodiments, X2is a halogen selected from the group consisting of fluorine, chlorine, bromine, and iodine. In some embodiments, X2is selected from the group consisting of chlorine and bromine. In one example, X2is chlorine. In one example, X2is bromine. In one example, X2is fluorine. In one example, X2is iodine. It will be appreciated that X1and X2may each be the same halide, or may otherwise each be a different halide.

[0263] In some embodiments, the dihalide compound of Formula 4 is selected from the group consisting of:

[0264]

[0265] Formula 4a; Formula 4b; Formula 4c; and Formula 4d.

[0266] In one example, the compound of Formula 4 is a compound of Formula 4b:

[0267]

[0268] Formula 4b.

[0269] The dihalide compound of Formula 4 may be provided in the N- acylation reaction in any molar equivalent amount suitable so as to effect the Wacylation reaction. In someembodiments, the dihalide compound of Formula 4 is provided in a molar equivalent amount of at least about 0.5, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 or 2.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the dihalide compound of Formula 4 is provided in a molar equivalent amount of less than about 10, 5, 3, 2, 1.5, 1.4, or 1.3, relative to the molar amount of the compound of Formula 3. In some embodiments, the dihalide compound of Formula 4 is provided in a molar equivalent amount of between about 0.1 and 20, between about 1.0 and 10, between about 1.1 and 5.0, or between about 1.2 and 1.7, relative to the molar amount of the compound of Formula 3. In one example, the ammonia reagent is provided in a molar equivalent amount of ammonia of about 1.5, relative to the molar amount of the compound of Formula 3.

[0270] In one example, the compound of Formula 3 is a compound of Formula 3a:

[0271]

[0272] Formula 3a.

[0273] In one example, the compound of Formula 3a is a compound of Formula 3a(R):

[0274]

[0275] Formula 3a( / ?).

[0276] In some embodiments, the N-acylation reaction is performed in the absence of a base reagent. In some embodiments, the N-acylation reaction is performed in the presence of a base reagent.

[0277] In some embodiments, the base reagent is an anionic base. In some embodiments, the base reagent is provided by a metal salt comprising a metal cation and counter anion selected from a bicarbonate, carbonate, hydroxide, oxide, or phosphate. In some embodiments, the base reagent is a metal salt comprising a Group 1 metal cation and counter anion selected from a bicarbonate, carbonate, hydroxide, oxide, or phosphate. In one example, the Group 1 metal is lithium, sodium, or potassium. In one example, the Group 1 metal is sodium. In one example, the Group 1 metal is potassium. In some embodiments, the base reagent is a metal carbonate. The metal carbonate may for example be selected from potassium carbonate (K2CO3), and sodium carbonate (Na2CO3). In some embodiments, the base reagent is a phosphate. The metalphosphate may be selected from tripotassium phosphate (K3PO4), dipotassium hydrogen phosphate (K2HPO4), sodium phosphate (Na3PO4), and disodium hydrogen phosphate (Na2HPO4). In some embodiments, the base reagent is selected from the group consisting of sodium hydroxide (NaOH), potassium hydroxide (KOH), potassium carbonate (K2CO3), potassium bicarbonate (KHCO3), sodium carbonate (Na2CO3), sodium bicarbonate (NaHCOs), tripotassium phosphate (K3PO4), dipotassium hydrogen phosphate (K2HPO4), sodium phosphate (Na3PO4), disodium hydrogen phosphate (Na2HPO4), and combinations thereof. In one example, the base reagent is potassium carbonate (K2CO3). It will be appreciated that the base reagent may be provided as an aqueous solution. Accordingly, in one example, the base reagent is potassium carbonate (K2CO3), and the potassium carbonate (K2CO3) is provided as an aqueous solution.

[0278] In some embodiments, the base reagent is an organic base. As will be appreciated by the person skilled in the art, an organic base is an organic compound that acts as a base. Organic bases are typically proton acceptors. Examples of organic bases include, but are not limited to, nitrogen-containing organic compounds. In one example, the organic base is an alkylamine. Examples of alkylamines include, but are not limited to, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, and diisopropylethylamine (DIPEA). In one example, the base reagent is triethylamine. In one example, the base reagent is diisopropylethylamine. In one example, the organic base is an aniline. Examples of anilines include, but are not limited to, aniline, 4-methoxyaniline, A, A-dimethylaniline, 3 -nitroaniline, and 4-trifluoromethylaniline. In one example, the base reagent is a pyridine derivative. Examples of pyridine derivatives include, but are not limited to, pyridine and pyrrolidine. In one example, the base reagent is an imidazole derivative. Examples of imidazole derivatives include, but are not limited to, imidazole and benzimidazole. In one example, the base reagent is quinoline. In one example, the base reagent is morpholine. In one example, the base reagent is piperidine. In one example the base is an amidine derivative. Examples of amidine derivates include, but are not limited to, diazabicycloundecene (DBU). In one example, the base is diazabicycloundecene (DBU).

[0279] The base reagent is provided in the A-acylation reaction at a particular concentration, defined by molarity (M, total moles of a solute per litre of solution, or solute concentration in a volume of solution). In some embodiments, the base reagent is provided in a concentration of at least about 0.5 M, 1.0 M, 1.5 M, 2.0 M, or 5.0 M. In some embodiments, the base reagent is provided in a concentration of less than about 20 M, 10 M, 5.0 M, 4.0 M, 3.0 M, or 2.0 M. In some embodiments, the base reagent is provided in a concentration of between about 0.5 M and10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M. In one example, the base reagent is provided in a concentration of about 2.0 M.

[0280] In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of at least about 0.5 M, 1.0 M, 1.5 M, 2.0 M, or 5.0 M. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of less than about 20 M, 10 M, 5.0 M, 4.0 M, 3.0 M, or 2.0 M. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of between about 0.5 M and 10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M. In one example, the base reagent is potassium carbonate (K2CO3), and is provided in a concentration of about 2.0 M.

[0281] The base reagent is provided in the N-acylation reaction at a particular stoichiometric amount. The base reagent may be provided in the N-acylation reaction in any molar equivalent amount suitable so as to effect the N-acylation reaction. In some embodiments, the base reagent is provided in a molar equivalent amount of at least about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is provided in a molar equivalent amount of less than about 10, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.5, 3.0, 2.5, or 2.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is provided in a molar equivalent amount of between about 0.5 and 5.0, between about 0.75 and 4.0, or between about 1.0 and 4.0, relative to the molar amount of the compound of Formula 3.

[0282] In some embodiments, the base reagent is potassium carbonate (K2CO3), and the potassium carbonate (K2CO3) may be provided in the N-acylation reaction in any molar equivalent amount suitable so as to effect the N-acylation reaction. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of at least about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of less than about 10, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.5, 3.0, 2.5, or 2.0, relative to the molar amount of the compound of Formula 3. In some embodiments, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of between about 0.5 and 5, between about 0.75 and 4.0, or between about 1.0 and 4.0, relative to the molar amount of the compound of Formula 3. In one example, the base reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of about 1.8, relative to the molar amount of the compound of Formula 3. In one example, thebase reagent is potassium carbonate (K2CO3), and is provided in a molar equivalent amount of about 3.4, relative to the molar amount of the compound of Formula 3.

[0283] As will be appreciated by the person skilled in the art, the A-acylation reaction will be performed in a suitable solvent. In one example, the A-acylation reaction is performed in the presence of an organic solvent. In some embodiments, the A-acylation reaction is performed in the presence of an organic solvent selected from the group consisting of a chlorinated hydrocarbon solvent, an ether solvent, and combinations thereof. In one example, the organic solvent is a chlorinated hydrocarbon solvent. In one example, the organic solvent is an ether solvent. In one example, the organic solvent is a combination of a chlorinated hydrocarbon solvent and an ether solvent.

[0284] Examples of chlorinated hydrocarbon solvents include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, trichloroethylene, and tetrachloroethylene. Accordingly, in one example, the organic solvent is dichloromethane. In one example, the organic solvent is chloroform.

[0285] Examples of ether solvents include, but are not limited to, diethyl ether, tetrahydrofuran, tetrahydropyran, 1,2-dimethoxyethane, methyl tert-butyl ether, 2-methyltetrahydrofuran, and 1,4-dioxane. Accordingly, in one example, the organic solvent is methyl tert-butyl ether. In one example, the organic solvent is tetrahydrofuran. In one example, the organic solvent is 2-methyltetrahydrofuran. In some embodiments, the organic solvent is selected from the group consisting of dichloromethane, methyl tert-butyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, and combinations thereof.

[0286] It may be preferable to initially cool the reaction mixture comprising the compound of Formula 3 prior to addition of the dihalide compound of Formula 4. In some embodiments, a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -30 °C and 10 °C, between about -20 °C and 10 °C, or between about -10 °C and 10 °C, immediately prior to the reaction with a dihalide compound of Formula 4. In one example, a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -10 °C and 10 °C immediately prior to the reaction with a dihalide compound of Formula 4.

[0287] Once the dihalide compound of Formula 4 has been added to the reaction mixture, it may be preferable to warm the reaction mixture. This temperature may be maintained until completion of the A-acylation reaction. In some embodiments, a reaction mixture comprising a compound of Formula 3 and a dihalide compound of Formula 4 is allowed to warm to between about 15 °C and 40 °C, between about 15 °C and 30 °C, or between about 15 °C and 25 °C, wherethe temperature is maintained until completion of the reaction. Completion of the reaction may be monitored by HPLC, as discussed herein. In some embodiments, the temperature of the reaction mixture is maintained for a reaction time (hours) of between about 1 and 12, between about 2 and 6, or between about 3 and 4.

[0288] In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2. In some embodiments, the N-acy lation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2, when measured at about 18 hours following commencement of the reaction. In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2 and when analysed by HPLC. In some embodiments, the AZ-acylation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2, when measured at about 18 hours following commencement of the reaction and when analysed by HPLC.

[0289] In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2a. In some embodiments, the N-acylation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2a, when measured at about 18 hours following commencement of the reaction. In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2a and when analysed by HPLC. In some embodiments, the N-acylation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2a, when measured at about 18 hours following commencement of the reaction and when analysed by HPLC.

[0290] In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2a'. In some embodiments, the N-acylation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2a', when measured at about 18 hours following commencement of the reaction. In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2a' and when analysed by HPLC. In some embodiments, the iV-acylationreaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2a', when measured at about 18 hours following commencement of the reaction and when analysed by HPLC.

[0291] In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2b. In some embodiments, the N-acylation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2b, when measured at about 18 hours following commencement of the reaction. In some embodiments, the N-acylation reaction provides at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2b and when analysed by HPLC. In some embodiments, the N-acylation reaction provides between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% conversion of the compound of Formula 3 to the compound of Formula 2b, when measured at about 18 hours following commencement of the reaction and when analysed by HPLC. In some embodiments, the N- acylation reaction provides a yield of a compound of Formula 2 of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 3 starting reagent. In some embodiments, the AZ-acylation reaction provides a yield of a compound of Formula 2 of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 3 starting reagent.

[0292] In some embodiments, the N-acylation reaction provides a yield of a compound of Formula 2a of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 3 starting reagent. In some embodiments, the N-acylation reaction provides a yield of a compound of Formula 2a of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 3 starting reagent.

[0293] In some embodiments, the N-acylation reaction provides a yield of a compound of Formula 2a' of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, as determined from a compound of Formula 3 starting reagent. In some embodiments, the N-acylation reaction provides a yield of a compound of Formula 2a' of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 3 starting reagent.

[0294] In some embodiments, the N-acylation reaction provides a yield of a compound of Formula 2b of at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99%, asdetermined from a compound of Formula 3 starting reagent. In some embodiments, the N-acylation reaction provides a yield of a compound of Formula 2b of between about 90% and 99.9%, 95% and 99.5%, or 98% and 99% as determined from a compound of Formula 3 starting reagent.

[0295] In some embodiments, the N-acylation reaction provides a compound of Formula 2 in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the AZ-acylation reaction provides a compound of Formula 2 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2 in the crude reaction mixture. In some embodiments, the N-acylation reaction provides a compound of Formula 2 in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2 isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the N-acylation reaction provides a compound of Formula 2 following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N-acylation reaction provides a compound of Formula 2 following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N- acylation reaction provides a compound of Formula 2 following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity.

[0296] In some embodiments, the N-acylation reaction provides a compound of Formula 2a in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the AZ-acylation reaction provides a compound of Formula 2a in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2a in the crude reaction mixture. In some embodiments, the N-acylation reaction provides a compound of Formula 2a in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2a isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the N- acylation reaction provides a compound of Formula 2a following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N-acylation reaction provides a compound of Formula 2a following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N-acylation reaction provides a compound of Formula 2a following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity.In some embodiments, the N-acylation reaction provides a compound of Formula 2a' in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the AZ-acylation reaction provides a compound of Formula 2a' in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2a' in the crude reaction mixture. In some embodiments, the N-acylation reaction provides a compound of Formula 2a' in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2a' isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the N- acylation reaction provides a compound of Formula 2a' following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N-acylation reaction provides a compound of Formula 2a' following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N-acylation reaction provides a compound of Formula 2a' following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity.

[0297] In some embodiments, the N-acylation reaction provides a compound of Formula 2b in at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity. Crystallisation can provide a purity of about 100%. In some embodiments, the AZ-acylation reaction provides a compound of Formula 2b in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2b in the crude reaction mixture. In some embodiments, the N-acylation reaction provides a compound of Formula 2b in at least 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.8%, or 99.9% purity of the compound of Formula 2b isolated from the reaction mixture (i.e., following the reaction work-up). In some embodiments, the N- acylation reaction provides a compound of Formula 2b following purification in at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N-acylation reaction provides a compound of Formula 2b following recrystallization in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity. In some embodiments, the N-acylation reaction provides a compound of Formula 2b following column chromatography in at least 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 99.9%, or 100% purity

[0298] In some embodiments, the N-acylation reaction beneficially reduces or avoids the generation of unwanted by-products, impurities, or residues. In some embodiments, preparing a compound of Formula 2 via an N-acylation reaction of a compound of Formula 3 with adihalide compound of Formula 4 results in reduced generation of any one or more unwanted by-products, impurities, or residues selected from the group consisting of:

[0299]

[0300] Impurity r; and Impurity s;

[0301] wherein R1and X1is as described herein.

[0302] In some embodiments, the N-acylation reaction beneficially reduces or avoids the generation of unwanted by-products, impurities, or residues. In some embodiments, preparing a compound of Formula 2a' via an N-acylation reaction of a compound of Formula 3a with a dihalide compound of Formula 4b results in reduced generation of any one or more unwanted by-products, impurities, or residues selected from the group consisting of:

[0303]

[0304] I

[0305]

[0306] In some embodiments, the N-acylation reaction beneficially reduces or avoids the generation of unwanted by-products, impurities, or residues. In some embodiments, preparing a compound of Formula 2a'(7?) via an N-acylation reaction of a compound of Formula 3a(7?) with a dihalide compound of Formula 4b results in reduced generation of any one or more unwanted by-products, impurities, or residues selected from the group consisting of:

[0307]

[0308] Impurity pa( / ?); Impurity qa( / ?);

[0309]

[0310] Impurity ra( / ?); and

[0311]

[0312] In some embodiments, the N-acylation reaction occurs with a starting material amount of a compound of Formula 2 of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg.

[0313] In some embodiments, the N-acylation reaction occurs with a starting material amount of a compound of Formula 2a of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg.

[0314] In some embodiments, the N-acylation reaction occurs with a starting material amount of a compound of Formula 2a' of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg. That is, the N-acylation reaction occurs on at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, or 40 kg scale.

[0315] In some embodiments, the N-acylation reaction occurs with a starting material amount of a compound of Formula 2b of at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, 40 kg, 50 kg, 100 kg, 250 kg, 500 kg, 750 kg, or 1000 kg. That is, the N-acylation reaction occurs on at least 1 g, 10 g, 50 g, 100 g, 500 g, 1 kg, 10 kg, 20 kg, 30 kg, or 40 kg scale.

[0316] In some embodiments, the N-acylation reaction further comprises reacting a compound of Formula 2 to form the compound of Formula 1:

[0317]

[0318] Formula 2 Formula 1;

[0319] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; and X1is a halogen, as defined herein.

[0320] In some embodiments, the N-acylation reaction further comprises reacting a compound of Formula 2 in the presence of a base reagent to form the compound of Formula 1:

[0321]

[0322] Formula 2 Formula 1;

[0323] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; and X1is a halogen, as defined herein. That is, in some embodiments, the N-acylation reaction further comprises the cyclisation reaction, as described herein, to form the bicyclic glycine -proline compound of Formula 1.

[0324] Overall Synthesis of a Bicyclic Glycine-Proline Compound of Formula 1

[0325] Provided herein is an example overall process for preparing a bicyclic glycine -proline compound of Formula 1(R), including Formula la(R) and Formula lb(R) (Formula la(R): cG-2-AllylP), as depicted in Scheme 3 below:

[0326]

[0327] Scheme 3. Exemplary process for the preparation of a bicyclic glycine -proline compound of Formula 1(R), including Formula 1a(R) and Formula 1b(R) (Formula 1a(R): cG-2-AllylP).

[0328] Accordingly, in some embodiments, the process the process for preparing a bicyclic -proline compound of Formula 1 comprises a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0329]

[0330] Formula 2 Formula 1;

[0331] wherein the process for preparing a compound of Formula 2 comprises an A-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0332]

[0333] Formula 3 Formula 4 Formula 2;

[0334] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; X1is a halogen; and X2is a halogen, as described herein.Accordingly, in some embodiments, the process for preparing a bicyclic -proline compound of Formula 1 comprises a cyclisation reaction of a compound of Formula 2 in the presence of a base reagent to form the compound of Formula 1:

[0335]

[0336] Formula 2 Formula 1;

[0337] wherein the process for preparing a compound of Formula 2 comprises an A-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0338]

[0339] Formula 3 Formula 4 Formula 2;

[0340] wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; X1is a halogen; and X2is a halogen, as described herein.

[0341] In some embodiments, the compound of Formula 2 may be isolated prior to the cyclisation reaction. In some examples, the compound of Formula 2 may be reacted in a subsequent reaction in situ or in crude form. In some examples, the compound of Formula 2 may be reacted without isolation and / or purification (i.e., reacted in situ). Similarly, in some embodiments, the compound of Formula 3 may be isolated prior to the A-acylation reaction. In some examples, the compound of Formula 3 may be reacted in a subsequent reaction in situ or in crude form. In some examples, the compound of Formula 3 may be reacted without isolation and / or purification (i.e., reacted in situ).

[0342] Scale-up Process

[0343] The process, as described herein, allows for the scalable synthetic pathway for the manufacture of a bicyclic glycine -proline compound of Formula 1. The process as described herein, for example when compared to the process described in international patent application W02005023815, can provide increased overall yield and purity of a compound of Formula 1 under scalable reaction conditions.In some embodiments, the process is conducted on small-scale (e.g., scale of 20 mg to 1 gram), as would be suitable for research and development purposes. However, in some other embodiments, the process is conducted on large-scale (e.g., scale of 1 kg to 2000kg), as would be suitable for manufacturing purposes. The synthesis or one or more steps thereof may occur as a batch-type process.

[0344] In some embodiments, the process for the preparation of a bicyclic glycine-proline compound of Formula 1 (i.e., the cyclisation reaction) occurs with a starting material amount of a compound of Formula 2 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a bicyclic glycine-proline compound of Formula 1 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0345] In some embodiments, the process for the preparation of a compound of Formula 2 (i.e., the N-acylation reaction) occurs with a starting material amount of a compound of Formula 3 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 2 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0346] In some embodiments, the process for the preparation of a compound of Formula 3 occurs with a starting material amount of a compound of Formula 5 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 3 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0347] In some embodiments, the process for the preparation of a compound of Formula 5 occurs with a starting material amount of a compound of Formula 6 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 5 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0348] In some embodiments, the process for the preparation of a compound of Formula 6 occurs with a starting material amount of a compound of Formula 7 of at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg. That is, the process for preparing a compound of Formula 6 occurs on at least 1 g, at least 10 g, at least 50 g, at least 100 g, at least 500 g, at least 1 kg, at least 10 kg, at least 25 kg, at least 50 kg, at least 75 kg, at least 100 kg, at least 500 kg, at least 1000 kg, at least 2000 kg, or at least 5000 kg scale.

[0349] In some embodiments, the process provides a molar conversion of a compound of Formula 2 to a bicyclic glycine-proline compound of Formula 1 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, or at least 98%, as measured by HPLC.

[0350] In some embodiments, the process provides a molar conversion of a compound of Formula 3 to a compound of Formula 2 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, or at least 98%, as measured by HPLC.

[0351] In some embodiments, the process provides a molar conversion of a compound of Formula 5 to a compound of Formula 3 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, or at least 98%, as measured by HPLC.

[0352] In some embodiments, the process provides a molar conversion of a compound of Formula 6 to a compound of Formula 5 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, or at least 98%, as measured by HPLC.

[0353] In some embodiments, the process provides a molar conversion of a compound of Formula 7 to a compound of Formula 6 of at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, or at least 98%, as measured by HPLC.

[0354] In some embodiments, the process provides a yield of a bicyclic glycine-proline compound of Formula 1 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound ofFormula 2 starting material. In some embodiments, the process of reacting a compound of Formula 2 to form the bicyclic glycine-proline compound of Formula 1, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a bicyclic glycine-proline compound of Formula 1.

[0355] In some embodiments, the process provides a yield of a compound of Formula 2 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 3 starting material. In some embodiments, the process of reacting a compound of Formula 3 to form the compound of Formula 2, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 2.

[0356] In some embodiments, the process provides a yield of a compound of Formula 3 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 5 starting material. In some embodiments, the process of reacting a compound of Formula 5 to form the compound of Formula 3, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 3.

[0357] In some embodiments, the process provides a yield of a compound of Formula 5 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 6 starting material. In some embodiments, the process of reacting a compound of Formula 6 to form the compound of Formula 5, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 5.

[0358] In some embodiments, the process provides a yield of a compound of Formula 6 of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, as determined from a compound of Formula 7 starting material. In some embodiments, the process of reacting a compound of Formula 7 to form the compound of Formula 6, as described herein, can provide between about 50% and 99.5%, between about 70% and 99.5%, or between about 80% and 99.5% yield, of a compound of Formula 6.

[0359] In some embodiments, the overall process of the synthesis of a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 7 (i.e., conversion of a compound of Formula 7 to Formula 6 to Formula 5 to Formula 3 to Formula 2 to Formula 1) provides an overall yield of between about 20% and about 95%, between about 30% and about 90%, between about 40% and about 85%, or between about 60% and about 80%. In one example, theprocess for preparing a bicyclic glycine -proline compound of Formula 1 from a compound of Formula 7 provides an overall yield of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0360] In some embodiments, the overall process of the synthesis of a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 3 (i.e., conversion of a compound of Formula 3 to Formula 2 to Formula 1) provides an overall yield of between about 20% and about 95%, between about 30% and about 90%, between about 40% and about 85%, or between about 60% and about 80%. In one example, the process for preparing a bicyclic glycine-proline compound of Formula 1 from a compound of Formula 3 provides an overall yield of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or 95%.

[0361] Compounds

[0362] In some embodiments, there is provided a bicyclic glycine-proline compound of Formula 1:

[0363]

[0364] Formula 1;

[0365] wherein R1is as defined herein, prepared by any one or more of the processes as described herein.

[0366] In some embodiments, there is provided a bicyclic glycine-proline compound of Formula la:

[0367]

[0368] Formula la;

[0369] prepared by any one or more of the processes as described herein.

[0370] In some embodiments, there is provided a bicyclic glycine-proline compound of Formula la(R):

[0371]

[0372] Formula la( / ?);

[0373] prepared by any one or more of the processes described herein.

[0374] In some embodiments, there is provided a compound of Formula 2:

[0375]

[0376] Formula 2;

[0377] wherein R1and X1are as defined herein, prepared by any one or more of the processes as described herein.

[0378] In some embodiments, there is provided a compound of Formula 2a':

[0379]

[0380] Formula 2a';

[0381] wherein R1and X1are as defined herein, prepared by any one or more of the processes as described herein.

[0382] In some embodiments, there is provided a compound of Formula 2a'(7?):

[0383]

[0384] Formula 2a '( / ?);

[0385] wherein R1and X1are as defined herein, prepared by any one or more of the processes as described herein.

[0386] In some embodiments, there is provided a compound of Formula 2(7 ):

[0387]

[0388] Formula 2( / ?);

[0389] wherein R1and X1are as defined herein, prepared by any one or more of the processes as described herein.

[0390] In some embodiments, there is provided a compound of Formula 2b:

[0391]

[0392] Formula 2b;

[0393] prepared by any one or more of the processes described herein.

[0394] In some embodiments, there is provided a compound of Formula 2b(R):

[0395]

[0396] Formula 2b( / ?);

[0397] prepared by any one or more of the processes described herein.

[0398] In some embodiments, there is provided a compound of Formula 2a:

[0399]

[0400] Formula 2a;

[0401] prepared by any one or more of the processes described herein.

[0402] In some embodiments, there is provided a compound of Formula 2a(R):

[0403]

[0404] Formula 2a(R);

[0405] prepared by any one or more of the processes described herein.

[0406] Compositions

[0407] Whilst a compound of Formula 1 or salt thereof may, in some embodiments, be administered alone, it is more typically administered as part of a pharmaceutical composition or formulation. Thus, the present disclosure also provides a pharmaceutical composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The pharmaceutical composition comprises one or more pharmaceutically acceptable diluents, carriers, or excipients (collectively referred to herein as “excipient” materials).

[0408] The present disclosure also provides pharmaceutical formulations or compositions, both for veterinary and for human medical use, which comprise compounds of Formula 1 of the present disclosure, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilisers, or the like. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.

[0409] The pharmaceutical formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing a compound of Formula 1, or pharmaceutically acceptable salt thereof, into association with the excipient that constitutes one or more necessary ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.

[0410] A tablet may be made for example by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active, or dispersing agent.Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored, and may be formulated so as to provide slow, pulsated or controlled release of the compound of Formula 1. The compound of Formula 1 can, for example, be administered in a form suitable for immediate release or controlled release. Immediate release or controlled release can be achieved by the use of suitable pharmaceutical compositions comprising a compound of Formula 1 or, particularly in the case of controlled release, by the use of devices such as subcutaneous implants or osmotic pumps. A compound of Formula 1 may also be administered liposomally.

[0411] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula 1 according to any embodiments or examples thereof as described herein:

[0412]

[0413] Formula 1;

[0414] wherein R1is as described herein, and the compound of Formula 1 is provided in high purity, for example in a wt% of at least about 95, 96, 97, 98, 99, 99.5, or 99.9. It will be appreciated that the high purity is in relation to any impurities that might be derived during its synthesis or purification. For example, any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein. It will be appreciated that the impurities relate to the byproducts of the process and not to any pharmaceutically acceptable excipients included in a pharmaceutical composition.

[0415] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula la according to any embodiments or examples thereof as described herein:

[0416]

[0417] Formula la;

[0418] wherein the compound of Formula la is provided in high purity, for example in a wt% of at least about 95, 96, 97, 98, 99, 99.5 or 99.9. It will be appreciated that the high purity is in relation to any impurities that might be derived during its synthesis or purification. For example, any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein. It will be appreciated that the impurities relate to the byproducts of the process and not to any pharmaceutically acceptable excipients included in a pharmaceutical composition.

[0419] In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein the compound of Formula la is provided in high purity, for example in a wt% of at least about 98. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein the compound of Formula la is provided in high purity, for example in a wt% of at least about 99. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein the compound of Formula la is provided in high purity, for example in a wt% of at least about 99.5. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein the compound of Formula la is provided in high purity, for example in a wt% of at least about 99.9. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1 a(R), wherein the compound of Formula 1a(R) is provided in high purity, for example in a wt% of at least about 98. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la(7?), wherein the compound of Formula la(7 ) is provided in high purity, for example in a wt% of at least about 99. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1 a(R), wherein the compound of Formula 1a(R) is provided in high purity, for example in a wt% of at least about99.5. In one example, there is provided a composition comprising a bicyclic glycine -proline compound of Formula la(7?), wherein the compound of Formula la(7 ) is provided in high purity, for example in a wt% of at least about 99.9.

[0420] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula la, according to any embodiments or examples thereof as described herein:

[0421]

[0422] Formula la;

[0423] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0424] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula la and one or more excipients, according to any embodiments or examples thereof as described herein:

[0425]

[0426] Formula la;

[0427] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula 1 a(7?), wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la(7?), wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1 a( / )) of less than about 0.5. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la(7?), wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1 a( / )) of less than about 0.1. In one example, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la(7?), wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0428] In some embodiments, there is provided a composition comprising a bicyclic glycine-proline compound of Formula la according to any embodiments or examples thereof as described herein:

[0429]

[0430] Formula la;

[0431] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may beselected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0432]

[0433] Impurity j; and Impurity k.

[0434] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula la and one or more excipients according to any embodiments or examples thereof as described herein:

[0435]

[0436] Formula la;

[0437] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0438]

[0439] Impurity a; Impurity b; Impurity c;

[0440]

[0441] Impurity g; Impurity h; Impurity i;

[0442]

[0443] Impurity j; and Impurity k.

[0444] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula la(7?) according to any embodiments or examples thereof as described herein:

[0445]

[0446] Formula la( / ?);

[0447] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0448]

[0449]

[0450] Impurity j( / ?); Impurity k(R); and Formula la(S).

[0451] In some embodiments, there is provided a composition comprising a bicyclic glycineproline compound of Formula la(7?) and one or more excipients according to any embodiments or examples thereof as described herein:

[0452]

[0453] Formula la( / ?);

[0454] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of:

[0455]

[0456] Impurity j( / ?); Impurity k(R); and Formula la(S).

[0457] The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0458] It will be appreciated that, in the process for preparing a compound of Formula 1 a(7?), the corresponding S-enantiomer, being a compound of Formula la(S), may, in some embodiments, be provided in the process. The presence of Formula la(S) in a composition comprising a compound of Formula la(7?), may be considered an impurity. This impurity may arise, for example, due to the presence of (S)-allylproline impurity in the (A’)-al lydprolincstarting material, which may be carried through the process described herein. Accordingly, in some embodiments, it is desirable to minimise the amount of a compound of Formula la(S) in a composition comprising a compound of Formula la(7?). It is typically difficult to separate enantiomers, particularly on large-scale and throughout commercial production. Beneficially, the process described herein provides for, in some embodiments, a composition comprising only trace amounts of a compound of Formula la(S).

[0459] Accordingly, in some embodiments, there is provided a composition comprising a compound of Formula la(7?) according to any embodiments or examples thereof as described herein:

[0460]

[0461] Formula la( / ?);

[0462] wherein a compound of Formula la(S):

[0463]

[0464] Formula la(S);

[0465] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0466] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula la(S), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula la(S), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula la(S), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein acompound of Formula la(S), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0467] In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula la(S), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 1a(S), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0468] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0469]

[0470] Formula la( / ?);

[0471] wherein a compound of Formula la(S):

[0472]

[0473] Formula la(S);

[0474] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0475] In one example, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 1a(S), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1 a(7?) and one or more excipients, wherein a compound of Formula la(S), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In oneexample, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 1a(S), if present, is in an amount (weight % of the amount of the compound of Formula la(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(R) and one or more excipients, wherein a compound of Formula la(S), if present, is in an amount (weight % of the amount of the compound of Formula la(R)) of less than about 0.05.

[0476] In some embodiments, there is provided a composition comprising a compound of Formula la(R) and one or more excipients, wherein a compound of Formula la(S), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 a(R) and one or more excipients, wherein a compound of Formula la(S), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0477] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0478]

[0479] Formula la;

[0480] wherein a compound of Formula 2:

[0481]

[0482] Formula 2;

[0483] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OC1-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; and X1is a halogen. The composition may be a pharmaceuticalcomposition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0484] In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0485] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0486] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients according to any embodiments or examples thereof as described herein:

[0487]

[0488] Formula la;

[0489] wherein a compound of Formula 2:

[0490]

[0491] Formula 2;

[0492] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OC1-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; and X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0493] In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0494] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0495]

[0496] Formula la;

[0497] wherein a compound of Formula 2a':

[0498]

[0499] Formula 2a';

[0500] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0501] In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0502] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a', if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a', if present, is in an amount of between about1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0503] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients according to any embodiments or examples thereof as described herein:

[0504]

[0505] Formula la;

[0506] wherein a compound of Formula 2a':

[0507]

[0508] Formula 2a';

[0509] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0510] In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein acompound of Formula 2a', if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0511] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a', if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a', if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0512] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0513]

[0514] Formula la;

[0515] wherein a compound of Formula 2a:

[0516]

[0517] Formula 2a;

[0518] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0519] In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less thanabout 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0520] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2a, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0521] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients according to any embodiments or examples thereof as described herein:

[0522]

[0523] Formula la;

[0524] wherein a compound of Formula 2a:

[0525]

[0526] Formula 2a;

[0527] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0528] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2a, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0529] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0530]

[0531] Formula la;

[0532] wherein a compound of Formula 2b:

[0533]

[0534] Formula 2b;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0535] In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0536] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2b, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein a compound of Formula 2b, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0537] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients according to any embodiments or examples thereof as described herein:

[0538]

[0539] Formula la;

[0540] wherein a compound of Formula 2b:

[0541]

[0542] Formula 2b;

[0543] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0544] In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0545] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2b, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2b, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0546] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0547]

[0548] Formula 1a(R);

[0549] wherein a compound of Formula 2(7?):

[0550]

[0551] Formula 2(R);

[0552] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OC1-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; and X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0553] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2(7?), if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1a) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2(R), if present, is in an amount (weight % of the amount of the compound of Formula 1a) of less than about 0.05.

[0554] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2(R), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2(R), if present, is in an amount of betweenabout 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0555] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0556]

[0557] Formula la( / ?);

[0558] wherein a compound of Formula 2(R)

[0559] h

[0560] NHR1

[0561] X1

[0562] Formula 2(R);

[0563] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OC1-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; and X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0564] In one example, there is provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1 a(7?) and one or more excipients, wherein a compound of Formula 2(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, thereis provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0565] In some embodiments, there is provided a composition comprising a compound of Formula la and one or more excipients, wherein a compound of Formula 2(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0566] In some embodiments, there is provided a composition comprising a compound of Formula la(7?) according to any embodiments or examples thereof as described herein:

[0567]

[0568] Formula 1a(R);

[0569] wherein a compound of Formula 2a'(7?):

[0570]

[0571] Formula 2a'(R);

[0572] if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0573] In one example, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2a'(R), if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound ofFormula 2a'(R), if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2a'(R), if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2a'(R), if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 0.05.

[0574] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2a'(R), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1a(R), wherein a compound of Formula 2a'(R), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0575] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0576]

[0577] wherein a compound of Formula 2a'(7?):

[0578]

[0579] Formula 2a'(R);

[0580] if present, is in an amount (weight % of the amount of the compound of Formula 1a(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein X1is a halogen. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.In one example, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2a'(A>). if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1 a(R) and one or more excipients, wherein a compound of Formula 2a'(A>). if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2a'(A>). if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2a'(A>). if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0581] In some embodiments, there is provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2a'(A>). if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 a(R) and one or more excipients, wherein a compound of Formula 2a'(^), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0582] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) according to any embodiments or examples thereof as described herein:

[0583]

[0584] wherein a compound of Formula 2a(R):

[0585]

[0586] Formula 2a(R);if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0587] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0588] In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2a(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2a(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0589] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0590]

[0591] Formula la( / ?);

[0592] wherein a compound of Formula 2a(R):

[0593]

[0594] Formula 2a(R);

[0595] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0596] In one example, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1 a(R) and one or more excipients, wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0597] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2a(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 a(R) and one or more excipients, wherein a compound of Formula 2a(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0598] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) according to any embodiments or examples thereof as described herein:

[0599]

[0600] Formula la( / ?);

[0601] wherein a compound of Formula 2b(7?):

[0602]

[0603] Formula 2b( / ?);

[0604] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0605] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0606] In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2b(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein a compound of Formula 2b(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0607] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0608]

[0609] Formula la( / ?);

[0610] wherein a compound of Formula 2b(7?):

[0611]

[0612] Formula 2b( / ?);

[0613] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0614] In one example, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 1 a(R) and one or more excipients, wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?) and one or more excipients, wherein a compound of Formula 2b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) and one or more excipients, wherein a compound of Formula 2b(R), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 a(R) and one or more excipients, wherein a compound of Formula 2b(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0615] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0616]

[0617] Formula la;

[0618] wherein Impurity a:

[0619]

[0620] Impurity a;

[0621] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0622] In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la,wherein Impurity a, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0623] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity a, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity a, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0624] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0625]

[0626] Formula la;

[0627] wherein Impurity b:

[0628]

[0629] Impurity b;

[0630] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0631] In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprisinga compound of Formula la, wherein Impurity b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity b, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0632] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity b, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity b, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0633] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0634]

[0635] Formula la;

[0636] wherein Impurity c:

[0637]

[0638] Impurity c;

[0639] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The compositionmay be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0640] In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity c, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0641] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity c, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity c, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0642] In some embodiments, there is provided a composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[0643]

[0644] Formula la;

[0645] wherein Impurity d:

[0646]

[0647] Impurity d;

[0648] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0649] In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity d, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity d, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity d, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la, wherein Impurity d, if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 0.05.

[0650] In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity d, if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity d, if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0651] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) according to any embodiments or examples thereof as described herein:

[0652]

[0653] Formula la( / ?);

[0654] wherein Impurity a(R):

[0655]

[0656] Impurity a( / ?);

[0657] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0658] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity a(R), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity a(R), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1 a(R), wherein Impurity a(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0659] In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity a(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 a(7?), wherein Impurity a(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0660] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) according to any embodiments or examples thereof as described herein:

[0661]

[0662] Formula 1a(R);

[0663] wherein Impurity b(R):

[0664]

[0665] Impurity b( / ?);

[0666] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0667] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity b(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0668] In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity b(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 a(7?), wherein Impurity b(7?), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0669] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) according to any embodiments or examples thereof as described herein:

[0670]

[0671] wherein Impurity c(R)

[0672]

[0673] Impurity c( / ?);

[0674] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0675] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity c(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity c(R), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity c(R), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 1 a(R), wherein Impurity c(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.

[0676] In some embodiments, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity c(7?), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula 1 a(7?), wherein Impurity c(7?), if present, is in an amount of between about 1 part per billion and about10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0677] In some embodiments, there is provided a composition comprising a compound of Formula 1a(R) according to any embodiments or examples thereof as described herein:

[0678]

[0679] wherein Impurity d(7?):

[0680]

[0681] Impurity d( / ?);

[0682] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0683] In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity d(R), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity d(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity d(R), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula la(7?), wherein Impurity d(7?), if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 0.05.In some embodiments, there is provided a composition comprising a compound of Formula la(R), wherein Impurity d(R), if present, is in an amount of about 1 part per billion. In some embodiments, there is provided a composition comprising a compound of Formula la, wherein Impurity d(R), if present, is in an amount of between about 1 part per billion and about 10 parts per billion, between about 1 part per billion and about 50 parts per billion, between about 1 part per billion and about 100 parts per billion, or between about 1 part per billion and about 1000 parts per billion.

[0684] In some embodiments, there is provided a composition comprising a compound of Formula 2 according to any embodiments or examples thereof as described herein:

[0685]

[0686] Formula 2;

[0687] wherein R1and X1are as defined herein, and wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0688] In some embodiments, there is provided a composition comprising a compound of Formula 2 and one or more excipients according to any embodiments or examples thereof as described herein:

[0689]

[0690] Formula 2;

[0691] wherein R1and X1are as defined herein, and wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantiallyfree of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0692] In one example, there is provided a composition comprising a compound of Formula 2, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2) of less than about 1. In one example, there is provided a composition comprising a compound of Formula 2, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2) of less than about 0.5. In one example, there is provided a composition comprising a compound of Formula 2, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2) of less than about 0.1. In one example, there is provided a composition comprising a compound of Formula 2, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2) of less than about 0.05.

[0693] In some embodiments, there is provided a composition comprising a compound of Formula 2a'( A’J according to any embodiments or examples thereof as described herein:

[0694]

[0695] Formula 2a'( / ?);

[0696] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a'(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of: HEIGHT="111" WIDTH="225" SRC="imgf000095_0002.tif" / >

[0697] Impurity ga( / ?); and Impurity ha( / ?).In some embodiments, there is provided a composition comprising a compound of Formula 2a'(R) and one or more excipients according to any embodiments or examples thereof as described herein:

[0698]

[0699] Formula 2a'( / ?);

[0700] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a'(R)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. In some embodiments, the impurities are selected from the group consisting of: HEIGHT="111" WIDTH="225" SRC="imgf000096_0002.tif" / >

[0701] Impurity ga( / ?); and Impurity ha( / ?).

[0702] In some embodiments, there is provided a composition comprising a compound of Formula 2b according to any embodiments or examples thereof as described herein:

[0703]

[0704] Formula 2b;

[0705] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2b) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or morepharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0706] In some embodiments, there is provided a composition comprising a compound of Formula 2b and one or more excipients according to any embodiments or examples thereof as described herein:

[0707]

[0708] Formula 2b;

[0709] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2b) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0710] In some embodiments, there is provided a composition comprising a compound of Formula 2a according to any embodiments or examples thereof as described herein:

[0711]

[0712] Formula 2a;

[0713] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.In some embodiments, there is provided a composition comprising a compound of Formula 2a and one or more excipients according to any embodiments or examples thereof as described herein:

[0714]

[0715] Formula 2a;

[0716] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2a) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001. The composition may be substantially free of any impurities. The impurities may be selected from any one or more of the by-products or reagents used in the processes as described herein. The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0717] The composition may be a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients according to any embodiments or examples thereof as described herein.

[0718] The present disclosure will now be described with reference to the following examples which illustrate some particular aspects of the present disclosure. However, it is to be understood that the particularity of the following description of the present disclosure is not to supersede the generality of the preceding description of the present disclosure.

[0719] Examples

[0720] The present disclosure is further illustrated by the following examples. These examples are offered by way of illustration only and are not intended to limit the scope of the disclosure.

[0721] Overall Synthesis

[0722] A non-limiting illustration of the overall synthesis used to obtain the bicyclic glycine-proline compound of Formula 1(R) is provided in Scheme 4.

[0723]

[0724] Scheme 4. Overall synthesis of Formula 1(R).

[0725] The pyrrolidine-2-carboxamide 3a( / ?) was prepared via a two-step sequence from the trichloromethyloxazolidinone 5, involving stereoselective allylation following by ammonolysis of the resulting alkylated bicyclic system using aqueous ammonia and slow addition of acetonitrile. Compound 3a( / ?) was isolated as an orange solid.

[0726] Example 1: Step 5

[0727] The cyclisation reaction of synthesized N-(2-haloacetyl)pyrrolidines 2a(R) and 2b(R) into the target compound 1a(R) was investigated using methanolic ammonia.

[0728] Preliminary test experiments were performed on a 100 mg scale in 8 mL screw-cap sealed glass vials with magnetic stirring. Compounds 2a( / ?) and 2b( / ?) were separately dissolved in the designated ammonia solutions (e.g. 7 N ammonia in MeOH, 10 equiv) and stirred at room temperature. Reaction progress was monitored by HPLC (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 h (si), 5 h (s2), ca. 20 h (s3), and 4 days (s4). The results are discussed herein.

[0729] Cyclisation Reaction of 2

[0730]

[0731] Protocols using 7 N ammonia in MeOH (at RT or 30 °C) were compared with lower ammonia concentration conditions (4 N ammonia in MeOH, and 2 N ammonia in MeOH). The effect of alternative solvents, such as ethanol and isopropanol on cyclization of 2b( / ?), was also examined.The results of the cyclisation reaction of A-(2-chloroacetyl)pyrrlidine-2-carboxamide 2b( / ?) with ammonia are summarised in Table 1.

[0732]

[0733] Impurity e( / ?); Impurity f( / ?); Impurity a( / ?);

[0734]

[0735] Impurity b( / ?); Impurity c( / ?); Impurity d( / ?).

[0736] Figure 1. Impurity identification from Table 1.

[0737] Observations

[0738] The reaction of compound 2b( / ?) with 7 N ammonia in methanol (10 equiv) at room temperature (entry 1; Modified “reaction Conditions A / B”) afforded the desired bicyclic system la( / ?) as major product (64%) after ca. 20 h, along with significant oligomeric side-products.

[0739] HPLC analysis after 1 h (si) revealed a complex product mixture including unreacted 2b( / ?) (22.78 area%), acyclic intermediates (e.g. amine 29; 22.52 / 13.51 area%), lactam 1 (12.68 area%), and oligomers [tentatively assigned as over-alkylated amines 30 (23.37 area%) and 31 (4.33 area%)]. By 20 h (s3), complete conversion of 2b( / ?) and acyclic intermediates was observed, resulting in compound la( / ?) as the main product (64.78 area%). However, significant amounts of oligomers (30 / 31) persisted and slightly increased over time. A minor new impurity, possibly a cyclic oligomer (e.g. 32), was also detected. Extended reaction times (up to 4 days) showed no notable changes.Effect of ammonia: lowering the ammonia concentration to 4 N (10 equiv; entry 2; “Reaction Conditions D”) and 2 N (10 equiv; entry 3; “Reaction Conditions C”) slowed the conversion (>20 h for completion), but resulted in a slight increase in compound la( / ?) yield while reducing the dimeric side -product 30 levels compared to the reference experiment with 7 N ammonia in MeOH (entry 1).

[0740] Effect of temperature: the reaction with 7 N ammonia in MeOH (10 equiv) at 30 °C (entry 4; “Reaction Conditions B”) showed a faster conversion rate than at room temperature (entry 1). In both cases, the final yields of compound la( / ?) (after 20 h) and the side-product levels remained comparable.

[0741] Effect of substrate concentration / ammonia amount: diluting the reaction by increasing the ammonia solution to 20 equiv (7 N ammonia in MeOH, entry 5; “Reaction Conditions A”) enhanced the efficiency, resulting in a higher yield of compound la( / ?) (77.47 area%) and lower levels of dimeric side-product 30 (18.37 area%) compared to the reference experiment using 10 equiv (entry 1). In contrast, concentrating the reaction by reducing the amount of ammonia to 5 equiv (4 N ammonia in MeOH, entry 6; “Reaction Conditions D”) led to a lower yield of compound la( / ?) (51.33 area%) and increased levels of the dimeric side -product 30 (28.99 area%) compared to the 10 equiv reaction conditions (entry 2). In both cases, complete conversion of 2b( / ?) and acyclic intermediates occurred within ca. 20 h at RT.

[0742] Summary

[0743] Among all tested conditions, the “Reaction Conditions A” (7 N ammonia in MeOH, 20 equiv, RT, ~20 h; entry 5) provided the highest yield of compound la( / ?) (77.5 area% by HPLC) from the cyclisation of 2b( / ?) while maintaining a comparable impurity profile.

[0744] Evaluation of Alternative Bases for the Cyclisation of 2b

[0745]

[0746] The cyclisation of compound 2b( / ?) was also examined using three alternative bases to ammonia (potassium hydroxide, sodium methoxide, and lithium bis(trimethylsilylamide). The results are shown in Scheme 5.

[0747]

[0748] Scheme 5. Reaction of -(2-chloroacetyl)pyrrolidine-2-carboxamide 2b( / ?) with KOH, NaOMe, and LiHMDS. Tentative structures of several detected side-products (based on preliminary MS data) are shown.

[0749] Observations

[0750] Treatment with KOH (5 equiv) in 1,4-dioxane at RT primarily led to oligomerisation, forming cyclic dimer 32 along with minor amounts of lactone 36 and lactam la( / ?) (4-6 area%). Heating at 60 °C resulted in amide hydrolysis, yielding proline 8.

[0751] Reaction with NaOMe (1.5 equiv; MeOH, 0 °C to RT) predominantly produced the methyl ether 39 (~91 area%), with only minor formation of la( / ?) (5-6 area%).

[0752] Treatment with LiHMDS (1.2 equiv; THF, 0 °C) resulted in complete consumption of 2b( / ?), generating a complex mixture of unidentified oligomers and hydrolysis products, with only trace amounts of la( / ?) (0.8%).

[0753] Summary

[0754] In summary, none of the alternative bases tested efficiently promoted lactam la( / ?) formation. Methanolic ammonia remained the most effective procedure.

[0755] Cyclisation Reaction of 2a

[0756]

[0757] The results of the cyclization of N-(2-bromoacetyl)pyrrolidine-2-carboxamide 2a( / ?) with methanolic ammonia (Route 2) are summarised in Table 2.

[0758]

[0759] Impurity a( / ?); Impurity b( / ?); Impurity c( / ?);

[0760]

[0761] 32

[0762] Exact Mass: 388.211

[0763] Mw: 388.468

[0764] Impurity d( / ?).

[0765] Figure 2. Impurity identification from Table 2.

[0766] Observations

[0767] Reaction of 2a( / ?) with 7 N ammonia in MeOH (10 equiv) at RT (entry 1; Modified “Reaction Conditions A / B”) afforded Compound la( / ?) as major product (58 area%) after ca.

[0768] 20 h, along with significant oligomeric side -products.

[0769] After 1 h (si), HPLC analysis revealed a complex product mixture including acyclic intermediates (e.g. amine 29; 20.72 / 13.25 area%), Compound la( / ?) (19.48 area%), and oligomers tentatively identified as over-alkylated amines 30 (36.50 area%) and 31 (9.51 area%). By 20 h (s3), complete conversion of the acyclic intermediates was observed, and Compound la( / ?) became the main product (58.00 area%). However, the side-products 30 / 31 remained and a minor new impurity, likely a cyclic oligomer (e.g. 32), was also detected. No significant changes were noted after longer reaction times (up to 4 days, s4), except for the slow conversion of impurity 30 to 32.

[0770] Effect of ammonia concentration: reducing the ammonia concentration to 4 N (10 equiv; entry 2, Modified “Reaction Conditions D”) and 2 N (10 equiv; entry 3, “Reaction Conditions C”) resulted in slower reaction rates. Complete conversion of acyclic intermediates (e.g. 29) required more than 20 h (only observed after 4 days, s4). After 20 h (s3), bothconditions produced similar yields of Compound la( / ?) and similar levels of oligomeric sideproducts (30-32) compared to the reference experiment with 7 N ammonia in MeOH (entry 1).

[0771] Effect of temperature: conducting the reaction with 7 N ammonia in MeOH (10 equiv) at 30 °C (entry 4; “Reaction Conditions B”) resulted in a faster initial conversion rate (sl-s2) than at room temperature (entry 1). However, after 20 h (s3), Compound la( / ?) yields and sideproduct levels (30-32) were similar in both cases.

[0772] Effect of substrate concentration / ammonia amount: diluting the reaction (half dilution) by increasing the amount of 7 N ammonia in MeOH to 20 equiv (entry 5, original “Reaction Conditions A”) improved the yield of Compound la( / ?) (~74 area%) while reducing the levels of oligomeric side -products 30-32 (29-30 combined area%) compared to the reference experiment with 10 equiv (entry 1). Conversely, concentrating the reaction (double concentration) by reducing the amount of 4 N ammonia in MeOH to 5 equiv (entry 6, “Reaction Conditions D”) resulted in a lower yield of Compound la( / ?) (~42 area%) and a significant increase in oligomeric side-products 30-32 (62-63 combined area%) compared to the 10 equiv reaction (entry 2). Despite these variations, complete conversion of acyclic intermediates (e.g.

[0773] 29) was consistently achieved after ca. 20 h at RT.

[0774] Summary

[0775] In summary, among all tested conditions, “Reaction Conditions A” (7 N ammonia in MeOH, 20 equiv, RT, ~20 h; entry 5) provided the best cyclisation results using 2a( / ?) as substrate (73.9 area% of Compound la( / ?) by HPLC).

[0776] Example 2: Step 4 (Part A)

[0777] A-acylation of the synthesized pyrrolidine-2-carboxamide 3a( / ?) was examined using bromoacetyl bromide and chloroacetyl chloride as alternative acylating agents under both “Reaction Conditions A” (2 M K2CO3 / CH2CI2) and “Reaction Conditions B” (2 M K2CO3 / 2-MeTHF).

[0778] Preliminary test experiments were performed on a 100 mg scale. Reaction progress was monitored by LCMS / HPLC after 1 hour at 0 °C (si), another hour at RT (s2) and ca. 18 h at RT (s3). The results are summarised in Tables 3a and 3b.I

[0779]

[0780] Figure 3. Impurity identification from Tables 3a and 3b.

[0781] Observations

[0782] A-acylation under “Reaction Conditions B” (2 M K2CO3 / 2-MeTHF, 1:1 v / v; entries 3-4, Table 3b) resulted in lower conversion rates compared to “Reaction Conditions A” conditions in CH2CI2 (entries 1-2, Table 3a). Additional amounts of the acylating reagent should be added at 0 °C to drive the reactions to completion.

[0783] When bromoacetyl bromide was used as acylating agent (entry 3), lower conversion rates and increased impurity levels were observed, even after 1 h at 0 °C, compared to reactions with chloroacetyl chloride (entry 4).The bromoacetamide product 2a( / ?) exhibited notable degradation after extended reaction times at RT (ca. 18 h), whereas the chloro acetamide derivative 2b( / ?) remained stable under similar conditions. To prevent degradation, reactions involving bromoacetyl bromide should be performed strictly at 0 °C under controlled conditions.

[0784] CH2CI2 proved to be a more favourable solvent than 2-MeTHF. In addition, “Reaction Conditions A” facilitated product isolation with improved yield and purity.

[0785] Summary

[0786] Overall, the 2-chloroacetamide 2b( / ?) demonstrated greater stability than the 2-bromoacetamide 2a( / ?) under acylation conditions, especially at RT, where the latter degraded more readily due to their higher reactivity.

[0787] Example 3: Step 4 (Part B)

[0788] Further analysis of the A-acylation reaction was undertaken using “Reaction Conditions C” and “Reaction Conditions D”. Specifically, the A- acylation reaction of the pyrrolidine 3 was examined under conditions using bromoacetyl bromide as the acylating agent. The results are summarised in Table 4.

[0789]

[0790] Figure 4. Impurity identification from Table 4.

[0791] Observations

[0792] The reaction of pyrrolidine 3a( / ?) under “Reaction Conditions C” using bromoacetyl bromide and triethylamine in chloroform (entry 1) afforded the desired bromoacetamide 2a( / ?), but with lower yields and purities than the standard aqueous / organic biphasic solvent system employed in “Reaction Conditions A” (entry 3) or “Reaction Conditions B” (entry 4) procedures. Moreover, these homogeneous reaction conditions introduced additional product-related impurities as detected by HPLC / LCMS and resulted in variable amounts of triethylammonium halide as a by-product in the isolated material.A-acylation of pyrrolidine 3a( / ?) under “Reaction Conditions D” (entry 2) produced results similar to those obtained under “Reaction Conditions A” (entry 3). When compound 3a( / ?) was used as the substrate, complete conversion was not achieved, and slightly higher impurity levels were observed after 1 hour of reaction.

[0793] Summary

[0794] In summary, neither the “Reaction Conditions D” nor the “Reaction Conditions C” provided significant improvements over the “Reaction Conditions A” procedure for the N-acylation of pyrrolidine 3a( / ?).108

[0795] Table 1. Cyclisation reaction of N-(2-chloroacetyl)pyrrolidine-2-carboxamide 2b(R) with ammonia.

[0796]

[0797] 109

[0798]

[0799] reviations: n.a. = not applicable; n.d. = not determined (product was not isolated).aPeak area measurement by manual integration (195 nm).bHPLC monitoring after 1 h (si), 5 h (s2), ca. 20 h (s3) and 4 days (s4) at RT.c / V-acy lated pyrrolidine 2b( / ?) was contaminated with minor product-related impurities (including 19 and 26).eSample was not measured.fForma white precipitate was observed after ca. 20 h at RT (s3).110

[0800] Table 2. Cyclisation reaction of N-(2-bromoacetyl)pyrrolidine-2-carboxamide 2a(R) with ammonia.

[0801]

[0802] Ill

[0803]

[0804] 112

[0805]

[0806] bbreviations: n.a. = not applicable; n.d. = not determined (product was not isolated).aPeak area measurement by manual integration (195 nm).bHPLC monitoring after 1 h (si), 5 (s2), ca. 20 h (s3) and 4 days (s4) at RT.c / V-acylated pyrrolidine 2a( / ?) containing minor product-related impurities (e.g. impurity at 6.04 min, 0.19 area%).113

[0807] able 3a. (V-acylation reaction of pyrrolidine-2-carboxamide 3a( / ?) with dihalide 4 (“Reaction Conditions A”).

[0808]

[0809]

[0810]

[0811]

[0812] Peak area measurement by manual integration (210 nm).bHPLC monitoring after 1 hour at 0°C (si), an additional hour at RT (s2) and overnight stirring at RT (ca. 18 h, s3).

[0813] able 3b. A-acylation reaction of pyrrolidine-2-carboxamide 3a( / ?) with dihalide 4 (“Reaction Conditions B”).

[0814]

[0815]

[0816] Peak area measurement by manual integration (210 nm).bHPLC monitoring after 1 hour at 0°C (si), an additional hour at RT (s2) and overnight stirring at RT (ca. rude material contained BHT (5-7 area% by HPLC; approx. 3-5 wt% by NMR) and residual 2-MeTHF (approx. 2-6 wt% by NMR).gA significant amount of prod emained in the aqueous layer.114

[0817] able 4.2V-acylation reaction of pyrrolidine 3a( / ?).

[0818]

[0819]

[0820] Peak area measurement by manual integration (210 nm).bHPLC monitoring after 1 hour (si) at -10 °C (entry 1) or 0°C (entries 2-4). The reactions were quenched after an addition our under these conditionscThe reaction mixture was not warmed up to RT and was instead run at 0°C.dThe biphasic reaction mixtures were stirred at 0 °C for 1 hour and then oom temperature overnight (ca. 18 h).eThe crude material contained BHT (5-7 area% by HPLC; approx. 3-5 wt% by NMR) and residual 2-MeTHF (approx. 2-6 wt% by NMR). significant amount of product 2b( / ?) remained in the aqueous layer.Example 4: Overall Conclusions Regarding Step 5 and Step 4

[0821] The cyclisation reaction (Step 5) and A-acylation reaction (Step 4) were thoroughly investigated in Examples 1-3 herein, and the key conclusions drawn are summarised below. Preparation of Compounds 2a(R) / 2b(R) (Step 4)

[0822] The A-acylation of pyrrolidine 3a( / ?) was investigated under various conditions using bromoacetyl bromide and chloroacetyl chloride as alternative acylating agents, including the “Reaction Conditions A” and “Reaction Conditions B” protocols. The key intermediates 2a( / ?) and 2b( / ?) were successfully synthesised, with a particular focus on optimizing the conditions for the preparation of the target Compound la( / ?). The optimal reaction conditions for each N-(2-haloacetyl)pyrrolidine product are summarised in Table 5.

[0823] The “Reaction Conditions B” protocol (2 M K2CO3 / 2-MeTHF) resulted in lower conversions and increased impurity levels, particularly when pyrrolidine-2-carboxamide 3a( / ?) and bromoacetyl bromide (4a) were used.

[0824] The 2-bromoacetamide product 2a( / ?) exhibited notable degradation under acylation conditions, especially at extended reaction times at room temperature, highlighting its higher reactivity and lower stability compared to the chloroacetyl derivative 2b( / ?).

[0825] When comparing the “Reaction Conditions A” and “Reaction Conditions B” acylation with conditions “Reaction Conditions C” and “Reaction Conditions D”, it was found that the established protocols provided superior yields, purity, and reaction efficiency. Neither the “Reaction Conditions D” (1 M K2CO3 / CH2CI2) nor “Reaction Conditions C” (EtsN / CHCE) conditions offered significant improvements over the “Reaction Conditions A” procedure, emphasising its robustness for the A-acylation of pyrrolidine 3a( / ?).

[0826] Table 5. Optimal reaction conditions for the A-acylation reaction of pyrrolidine

[0827]

[0828]

[0829]

[0830] aHPLC analysis (sc_base_mcpr, 210 nm) performed after 1 h at 0 °C. Peak area was measured by manual integration.bIncomplete conversion: 1.49 area% of unreacted 3a(R).

[0831] Preparation of Compound 1 ( Step 5 )

[0832] The cyclisation of A-(2-haloacetyl)pyrrolidine-2-carboxamides 2a( / ?) / 2b( / ?) was systematically investigated to optimise the synthesis of Compound la( / ?). In this context, cyclisation with methanolic ammonia was examined under “Reaction Conditions A”, “Reaction Conditions B”, “Reaction Conditions C” and “Reaction Conditions D”. The results demonstrated that substrate selection, ammonia concentration, solvent, and temperature significantly influenced reaction efficiency, yield, and impurity profile. Optimal cyclization conditions were identified for each substrate, as shown in Table 6.

[0833] Carboxamides 2a( / ?) and 2b( / ?): The best conditions were identified as “Reaction Conditions A”.

[0834] Table 6. Optimal reaction conditions for the cyclisation reaction of 2a( / ?) / 2b( / ?).

[0835]

[0836]

[0837] aHPLC analysis (XBridge-C18_05-80_Phos, 195 nm) performed after ca. 20 h of reaction. Peak area was measured by manual integration.

[0838] Example 5: General Experimental

[0839] N-Acylation Reaction of Pyrrolidine 3

[0840] “Reaction Conditions A” - General Experimental Procedure

[0841] The reaction was performed in an 8 mL glass vial equipped with a stirring bar. Potassium carbonate, 2 M in water (3.4 equiv), was added to a stirred solution of the pyrrolidine-2-carboxamide 3a( / ?) in CH2CI2 (11 vol) and the mixture was cooled to 0 °C (icebath). The dihalide 4a / 4b (1.5 equiv) was then added drop wise. The biphasic reaction mixture was vigorously stirred (1400 rpm) at 0 °C for 1 hour and then at room temperature overnight. LCMS / HPLC (sc_base, 210 nm) monitoring after 1 hour at 0 °C (si), an additional hour at RT (s2), and ca. 18 h at RT (s3). The reaction mixture was partitioned between water (10 vol) and CH2CI2 (10 vol), and the aqueous layer (pH 8-9) was further extracted with CH2CI2 (10 vol). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0842] “Reaction Conditions B” - General Experimental Procedure

[0843] The reaction was performed in an 8 mL glass vial equipped with a stirring bar. Potassium carbonate, 2 M in water (1.8 equiv), was added to a stirred solution of the pyrrolidine-2-carboxamide 3a( / ?) in 2-MeTHF (6 vol) and the mixture was cooled to 0 °C (ice bath). The dihalide 4a / 4b (1.5 equiv) was then added drop wise. The biphasic reaction mixture was vigorously stirred (1400 rpm) at 0 °C for 1 hour and then at room temperature overnight. LCMS / HPLC (sc_base, 210 nm) monitoring after 1 hour at 0 °C (si), an additional hour at RT (s2), and ca. 18 h at RT (s3). The reaction mixture was diluted with 2-MeTHF (10 vol), and the aqueous layer (pH 8-9) was separated and discarded. The organic layer was washed with aqueous NaCl (25% w / v; 10 vol), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0844] “Reaction Conditions C” - General Experimental Procedure

[0845] The reaction was performed in an 8 mL glass vial equipped with a stirring bar under nitrogen. A solution of pyrrolidine-2-carboxamide 3a( / ?) in CDCI3 (12.3 vol) was cooled to -10 °C (ice / salt bath) and treated sequentially with triethylamine (2.4 equiv) and dihalide 4a / 4b (2.4 equiv) in CDCI3 (12.3 vol). After stirring for 2 h at -10 °C (HPLC / LCMS monitoring), the reaction was quenched with water (12.3 vol) and the layers were separated (aqueous layer was discarded; pH 2). The organic layer was washed with sat. aq. NaHCOs (12.3 vol; pH 8), brine (12.3 vol; pH 7), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0846] “Reaction Conditions D” - General Experimental Procedure

[0847] The reaction was performed in an 8 mL glass vial equipped with a stirring bar under nitrogen. Potassium carbonate, 1 M in water (1.3 equiv) was added to a solution of pyrrolidine -2-carboxamide 3a( / ?) in CH2CI2 (25 vol) and the mixture was cooled to 0 °C (ice bath). The dihalide 4a / 4b (1.3 equiv) was added in one portion to the vigorously stirred biphasic solution. The reaction mixture was stirred at 0 °C for 2 h (HPLC / LCMS monitoring). The organic layerwas separated, and the aqueous layer (pH 8-9) was further extracted with CH2CI2 (2 x 14 vol). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the crude acylated product.

[0848] Preparation of Compound 2b(R)

[0849] The reaction was performed in 100 mL glass round-bottom flask with magnetic stirring. Potassium carbonate, 2 M in water (17 mL, 3.4 equiv), was added to a stirred solution of the pyrrolidine-2-carboxamide 3a( / ?) (1.5 g, 9.70 mmol) in CH2CI2 (17 mL, 11 vol) and the mixture was cooled to 0 °C (ice bath). 2-Chloroacetyl chloride (1.5 equiv) was then added dropwise. The biphasic (yellow) reaction mixture was vigorously stirred at 0 °C for 1 hour and then at room temperature overnight. The reaction mixture was partitioned between water (10 vol) and CH2CI2 (10 vol), and the aqueous layer (pH 8) was further extracted with CH2CI2 (10 vol). The combined organic layers were dried over Na2SC>4, filtered and concentrated under reduced pressure to afford the crude acylated product 2b( / ?) as an orangish-yellow sticky semisolid (92.92 area% by HPLC, 210 nm). This material was combined with the crude 2b( / ?) obtained from previous experiment in a single batch (79-C, 2.61 g) and then purified by flash chromatography (silica gel, 90-100% EtOAc in heptane) to provide the N-(2-chloroacetyl)pyrrolidine 2b( / ?) (1.80 g, batch 22020153-79-C-l) as a white solid (98.25% purity by HPLC), containing minor product-related impurities including side -products 19 and 26.

[0850] Preparation of Compound 2a(R)

[0851] Potassium carbonate, 2 M in water (15.6 mL, 4 equiv), was added to a stirred solution of the pyrrolidine-2-carboxamide 3a( / ?) (1.2 g, 7.78 mmol) in CH2CI2 (15.6 mL, 13 vol) at 0 °C (ice bath). After 5 min, 2-bromoacetyl chloride (1.5 equiv) was added dropwise and the slightly yellow biphasic mixture was stirred at 0 °C for 45 min and then at room temperature for another 1.5 h (full conversion by LCMS). The reaction mixture was partitioned between water (11.5 vol) and CH2CI2 (11.5 vol), and the aqueous layer was further extracted with CH2CI2 (2x11.5 vol). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue (yellow oil, ca. 2.0 g) was purified by flash chromatography (silica gel, 60-100% EtOAc in heptane) to provide the A-(2-bromoacetyl)pyrrolidine 2a( / ?) (1.49 g, 70% yield; batch 22020153-82-A) as an off-white solid (98.90% purity by HPLC at 195 nm).

[0852] Cyclisation Reaction of Pyrrolidine 2a(R) / 2b(R)“Reaction Conditions A” - General Experimental Procedure

[0853] The reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2a( / ?) / 2b( / ?) was dissolved in 7 N ammonia solution in MeOH (20 equiv; 12.4 vol) and the mixture was stirred at room temperature. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four intervals: 1 h (si), 5 h (s2), ca. 20 h (s3), and 4 days (s4). After 4 days at RT, the reaction mixture was discarded without further treatment.

[0854] “Reaction Conditions B” - General Experimental Procedure

[0855] The reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2a( / ?) / 2b( / ?) was dissolved in 7 N ammonia solution in MeOH (10 equiv; 5.8 vol) and the mixture was stirred at 30 °C. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 hour (si), 5 hours (s2), ca. 20 hours (s3), and 4 days (s4). After 4 days at 30 °C, the reaction mixture was discarded without further treatment.

[0856] “Reaction Conditions C” - General Experimental Procedure

[0857] The reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2a( / ?) / 2b( / ?) was dissolved in 2 N ammonia solution in MeOH (10 equiv; 17.2 vol) and the mixture was stirred at room temperature. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 hour (si), 5 hours (s2), ca. 20 hours (s3), and 4 days (s4). After 4 days at RT, the reaction mixture was discarded without further treatment.

[0858] “Reaction Conditions D” - General Experimental Procedure

[0859] The reaction was performed in an 8 mL glass vials equipped with stirring bar and sealed with a Thermoset screw cap. Compound 2a( / ?) / 2b( / ?) was dissolved in 4 N ammonia solution in MeOH (5 equiv; 4.5 vol) and the mixture was stirred at room temperature. Reaction progress was monitored by HPLC / LCMS (XBridge-C18_05-80_Phos, 195 nm) at four time points: 1 hour (si), 5 hours (s2), ca. 20 hours (s3), and 4 days (s4). After 4 days at RT, the reaction mixture was discarded without further treatment.

[0860] N -Acylation Reaction of Pyrrolidine 3b (Secondary Amide)

[0861] The reaction was performed on 1.0 g scale. Compound 3b was combined with 1 M K2CO3 in dichloromethane, and stirred at room temperature for 4.5 h. The reaction mixture was separated, and the organic phase concentrated to give 1.42 g of a yellow oil (112% crude yield). LCMS indicated a roughly 1: 1 mixture of Compound 2c / 2d had formed. This indicated thathalogen exchange of Br to Cl occurs rapidly over time. Using column chromatography (silica, heptane / EtOAc (20 —> 90%)), 587 mg of a slightly turbid colourless oil was obtained, containing a 1:1 mixture of Compound 2c / 2d (inseparable).

[0862] Cyclisation reaction of Pyrrolidine 2c / 2d (Secondary Amide)

[0863] The cyclisation reaction was performed according to literature conditions (Chem. Commun., 2019, 55, 3931-3934) using TEBAC and NaOH in dichloromethane, with the exception that the literature reported 12.5 M NaOH was replaced with 5.0 M NaOH. Initially, the cyclisation reaction was performed on 100 mg scale. The cyclisation reaction was slow: after 24 h, 65 area% of Compound 2c and Compound 2d on LCMS remained. Another 0.5 mL of NaOH 1.0 M was then added, and the temperature raised to 40 °C. After another 23 h of stirring, this gave 56 area% of Compound lb.

[0864] Analytical Methods

[0865] HPLC Method: Sc_Base_MCPR (210 nm)

[0866] Instrument: Agilent 1260. Bin. Pump: G1312B, Degasser. Autosampler 1260. Column Comp. 1260. Detection: G1315C DAD (210, 220 and 210-320 nm), PDA (210-320 nm). Column: Waters XSelect CSH C18 (50x2.1 mm, 3.5 pm). Flow: 0.8 mL / min. Column temp: 25°C. Eluent A: 10 mM NH4HCO3 in MilliQ water (pH 9.5). Eluent B: acetonitrile. Gradient: t=0 min 5% B, t=4.5 min 98% B, t=6 min 98% B. Postrun: 2 min, 5% B.

[0867] LCMS Method: Sc_Base (210 nm)

[0868] Instrument: Agilent 1260 Infinity II. Bin. Pump: 1260 G7112B. Multisampler: 1260 G7167A. 1260 MCT G7116A Column Comp.: 1260 MCT G7116A. Detection: DAD G7115A (210, 220 and 210-320 nm), PDA (210-320 nm), MSD G6130B (ESI pos / neg) mass range 90- 1500. Column: XSelect CSH C18 (30x2.1 mm, 3.5 pm). Flow: 1 mL / min, Column temp: 25°C. Eluent A: 10 mM NH4HCO3 in water (pH 9.5). Eluent B: acetonitrile. Gradient: t=0 min 5% B, t=1.6 min 98% B, t=3 min 98% B. Postrun: 1.2 min.

[0869] HPLC Method: XBridge-C18_05-80_Phos (195 nm)

[0870] Instrument: Agilent 1100. Quat. Pump: G1311A. Autosampler 1100. Column Comp.

[0871] 1100. Detection: G1315A DAD (195 nm and 210-320 nm). Column: XBridge C18 (150x4.6mm, 3.5 pm). Flow: 1.0 mL / min. Column temp: 30°C. Eluent A: 0.1% Phosphoric acid in MilliQ water. Eluent B: acetonitrile. Gradient: t=0 min 5% B, t=0.1 min 5% B, t= 10 min 35% B, t=15 min 80% B, t=19 min 80% B, t=20 min 5% B, t=25 min 5% B.LCMS Method: XBridge-C18_05-80_FA (195 nm)

[0872] Instrument: Agilent 1260 Infinity with SQ-MSD. Quat. Pump: G1311A. Autosampler 1100. Column Comp. 1100. Detection: DAD G1315A (195 nm and 210-320 nm), PDA (210-320 nm), MSD G6130B (ESI pos / neg) mass range 100-1000. Column: XBridge C18 (150x4.6mm, 3.5 μm). Flow: 1.0 mL / min. Column temp: 30°C. Eluent A: 0.1% Formic acid in water. Eluent B: 0.1% Formic acid in MeCN. Gradient: t=0 min 5% B, t=0.1 min 5% B, t=10 min 35% B, t=15 min 80% B, t=19 min 80% B, t=20 min 5% B, t=25 min 5% B.Itemised List of Embodiments

[0873] 1. A process for preparing a bicyclic glycine -proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:

[0874]

[0875] Formula 2 Formula 1;

[0876] wherein

[0877] R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; and

[0878] X1is a halogen.

[0879] 2. The process of item 1, wherein the cyclisation reaction is performed in the presence of a base reagent.

[0880] 3. The process of item 1 or item 2, wherein R1is -H.

[0881] 4. The process of any one of items 1 to 3, wherein X1is chlorine.

[0882] 5. The process of any one of items 2 to 4, wherein the base reagent is selected from the group consisting of an ammonia reagent, a metal alkoxide, a metal carbonate, a metal phosphate, a metal hydroxide, a metal hydride, a metal amine, a metal silylamide, and a combination thereof.

[0883] 6. The process of item 5, wherein the ammonia reagent is selected from the group consisting of ammonia in organic solvent, gaseous ammonia, liquid ammonia, sodium amide, and combinations thereof.

[0884] 7. The process of item 5 or item 6, wherein the ammonia reagent is ammonia in organic solvent.

[0885] 8. The process of any one of items 5 to 7, wherein the organic solvent is an alcoholic solvent, and the ammonia reagent is selected from the group consisting of ammonia in methanol solvent, ammonia in ethanol solvent, ammonia in isopropyl solvent, and combinations thereof.9. The process of any one of items 5 to 8, wherein the ammonia reagent is ammonia in methanol solution.

[0886] 10. The process of any one of items 5 to 9, wherein the ammonia reagent is provided in a concentration of between about 1.0 N and 10 N, between about 4.0 N and 9.0 N, or between about 6.0 N and 8.0 N.

[0887] 11. The process of any one of items 5 to 10, wherein the ammonia reagent is provided in a molar equivalent amount of ammonia of between about 0.1 and 40, between about 1.0 and 30, between about 5.0 and 25, or between about 5.0 to 20 relative to the molar amount of the compound of Formula 2.

[0888] 12. The process of any one of items 1 to 11, wherein the cyclisation reaction is performed in the presence of a chlorinated hydrocarbon solvent, an ether solvent, an organic nitrile solvent, an alcohol solvent, or a combination thereof.

[0889] 13. The process of any one of items 1 to 12, wherein the cyclisation reaction is performed at a temperature of between about between about 10 °C and 50 °C, between about 20 °C and 40 °C, or between about 25 °C and 35 °C.

[0890] 14. The process of any one of items 1 to 13, wherein the cyclisation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1.

[0891] 15. The process of item 1, wherein the compound of Formula 2 is a compound of Formula 2b:

[0892]

[0893] Formula 2b.

[0894] 16. The process of any one of items 1 to 15, further comprising preparing a compound of Formula 2 via an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0895]

[0896] Formula 3 Formula 4 Formula 2;

[0897] wherein

[0898] R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl;

[0899] X1is a halogen; and

[0900] X2is a halogen.

[0901] 17. The process of item 16, wherein R1is -H.

[0902] 18. The process of item 16 or item 17, wherein X1is chlorine and X2is chlorine.

[0903] 19. The process of any one of items 16 to 18, wherein the dihalide compound of Formula 4 is provided in a molar equivalent amount of between about 0.1 and 20, between about 1.0 and 10, between about 1.1 and 5, or between about 1.2 and 1.7, relative to the molar amount of the compound of Formula 3.

[0904] 20. The process of any one of items 16 to 19, wherein the N-acylation reaction is performed in the presence of a base reagent.

[0905] 21. The process of item 20, wherein the base reagent is potassium carbonate (K2CO3).

[0906] 22. The process of item 21, wherein the potassium carbonate (K2CO3) is provided as an aqueous solution.

[0907] 23. The process of item 21 or item 22, wherein the aqueous potassium carbonate solution has a concentration of between about 0.5 M and 10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M.

[0908] 24. The process of any one of items 21 to 23, wherein the potassium carbonate (K2CO3) is provided in a molar equivalent amount of between about 0.5 and 5.0, between about 0.75 and 4.0, or between about 1.0 and 3.0, relative to the molar amount of the compound of Formula 3.

[0909] 25. The process of any one of items 16 to 24, wherein the N-acylation reaction is performedin the presence of a chlorinated hydrocarbon solvent, an ether solvent, or a combination thereof.

[0910] 26. The process of item 25, wherein the organic solvent is dichloromethane (DCM).

[0911] 27. The process of item 25, wherein the organic solvent is 2 -methyltetrahydrofuran (2-MeTHF).

[0912] 28. The process of any one of items 16 to 27, wherein a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -30 °C to 10 °C, between about -20 °C to 10 °C, or between about -10 °C to 10 °C, immediately prior to the reaction with a dihalide compound of Formula 4.

[0913] 29. The process of any one of items 16 to 28, wherein a reaction mixture comprising a compound of Formula 3 and a dihalide compound of Formula 4 is allowed to warm to between about 10 °C and 50 °C, between about 15 °C and 40 °C, between about 15 °C and 30 °C, or between about 15 °C and 25 °C, where the temperature is maintained until completion of the reaction.

[0914] 30. The process of any one of items 16 to 29, wherein the N-acylation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2.

[0915] 31. The process of item 16, wherein the compound of Formula 3 is a compound of Formula 3a:

[0916]

[0917] Formula 3a.

[0918] 32. The process of any one of items 1 to 31, wherein the bicyclic glycine-proline compound of Formula 1 is a bicyclic glycine-proline compound of Formula 1(R):

[0919]

[0920] Formula 1(R).33. A bicyclic glycine-proline compound of Formula la:

[0921]

[0922] Formula la;

[0923] prepared by the process of any one of items 1 to 31.

[0924] 34. A process for preparing a compound of Formula 2, comprising an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:

[0925]

[0926] Formula 3 Formula 4 Formula 2;

[0927] wherein

[0928] R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl;

[0929] X1is a halogen; and

[0930] X2is a halogen.

[0931] 35. The process of item 34, wherein the compound of Formula 3 is a compound of Formula 3a:

[0932]

[0933] Formula 3a.

[0934] 36. The process of item 34 or item 35, further comprising reacting a compound of Formula 2 to form the compound of Formula 1:

[0935]

[0936] Formula 2 Formula 1;

[0937] wherein

[0938] R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; and

[0939] X1is a halogen.

[0940] 37. The process of item 36, wherein R1is -H.

[0941] 38. The process of item 36 or item 37, wherein X1is chlorine.

[0942] 39. A composition comprising a bicyclic glycine -proline compound of Formula la:

[0943]

[0944] Formula la;

[0945] and one or more excipients, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, or 0.0001.

[0946] 40. A composition comprising a bicyclic glycine -proline compound of Formula la:

[0947]

[0948] Formula la;

[0949] and one or more excipients, wherein the composition is substantially free of impurities.

[0950] 41. A composition comprising a compound of Formula 2b:

[0951]

[0952] Formula 2b;

[0953] wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2b) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0954] 42. A composition comprising a compound of Formula la:

[0955]

[0956] Formula la;

[0957] wherein a compound of Formula 2:

[0958]

[0959] Formula 2;

[0960] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OC1-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; and X1is a halogen.

[0961] 43. A composition comprising a compound of Formula la:

[0962]

[0963] Formula la;wherein a compound of Formula 2a':

[0964]

[0965] Formula 2a';

[0966] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein X1is a halogen.

[0967] 44. A composition comprising a compound of Formula la:

[0968]

[0969] Formula la;

[0970] wherein Impurity g:

[0971]

[0972] Impurity g;

[0973] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0974] 45. A composition comprising a compound of Formula la:

[0975]

[0976] Formula la;

[0977] wherein Impurity h:

[0978]

[0979] Impurity h;

[0980] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0981] 46. A composition comprising a compound of Formula la:

[0982]

[0983] Formula la;

[0984] wherein Impurity i:

[0985]

[0986] Impurity i;

[0987] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0988] 47. A composition comprising a compound of Formula la:

[0989]

[0990] Formula la;

[0991] wherein Impurity j:

[0992]

[0993] Impurity j;

[0994] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[0995] 48. A composition comprising a compound of Formula la:

[0996]

[0997] Formula la;

[0998] wherein Impurity k:

[0999]

[1000] Impurity k;

[1001] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1002] 49. A composition comprising a compound of Formula la(7?):

[1003]

[1004] Formula la( / ?);

[1005] wherein Impurity la(S):

[1006]

[1007] Impurity la(S);

[1008] if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1009] 50. A composition comprising a compound of Formula la:

[1010]

[1011] Formula la;

[1012] wherein Impurity a:

[1013]

[1014] Impurity a;

[1015] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1016] 51. A composition comprising a compound of Formula la:

[1017]

[1018] Formula la;

[1019] wherein Impurity b:

[1020]

[1021] Impurity b;

[1022] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1023] 52. A composition comprising a compound of Formula la:

[1024]

[1025] Formula la;

[1026] wherein Impurity c:

[1027]

[1028] Impurity c;

[1029] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

[1030] 53. A composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:

[1031]

[1032] Formula la;

[1033] wherein Impurity d:

[1034]

[1035] Impurity d;

[1036] if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

Claims

Claims1. A process for preparing a bicyclic glycine -proline compound of Formula 1 comprising a cyclisation reaction of a compound of Formula 2 to form the compound of Formula 1:Formula 2 Formula 1;whereinR1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; andX1is a halogen.

2. The process of claim 1, wherein the cyclisation reaction is performed in the presence of a base reagent.

3. The process of claim 1 or claim 2, wherein R1is -H.

4. The process of any one of claims 1 to 3, wherein X1is chlorine.

5. The process of any one of claims 2 to 4, wherein the base reagent is selected from the group consisting of an ammonia reagent, a metal alkoxide, a metal carbonate, a metal phosphate, a metal hydroxide, a metal hydride, a metal amine, a metal silylamide, and a combination thereof.

6. The process of claim 5, wherein the ammonia reagent is selected from the group consisting of ammonia in organic solvent, gaseous ammonia, liquid ammonia, sodium amide, and combinations thereof.

7. The process of claim 5 or claim 6, wherein the ammonia reagent is ammonia in organic solvent.

8. The process of any one of claims 5 to 7, wherein the organic solvent is an alcoholic solvent, and the ammonia reagent is selected from the group consisting of ammonia in methanol solvent, ammonia in ethanol solvent, ammonia in isopropyl solvent, and combinations thereof.

9. The process of any one of claims 5 to 8, wherein the ammonia reagent is ammonia inmethanol solution.

10. The process of any one of claims 5 to 9, wherein the ammonia reagent is provided in a concentration of between about 1.0 N and 10 N, between about 4.0 N and 9.0 N, or between about 6.0 N and 8.0 N.

11. The process of any one of claims 5 to 10, wherein the ammonia reagent is provided in a molar equivalent amount of ammonia of between about 0.1 and 40, between about 1.0 and 30, between about 5.0 and 25, or between about 5.0 to 20, relative to the molar amount of the compound of Formula 2.

12. The process of any one of claims 1 to 11, wherein the cyclisation reaction is performed in the presence of a chlorinated hydrocarbon solvent, an ether solvent, an organic nitrile solvent, an alcohol solvent, or a combination thereof.

13. The process of any one of claims 1 to 12, wherein the cyclisation reaction is performed at a temperature of between about between about 10 °C and 50 °C, between about 20 °C and 40 °C, or between about 25 °C and 35 °C.

14. The process of any one of claims 1 to 13, wherein the cyclisation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 2 to the compound of Formula 1.

15. The process of claim 1, wherein the compound of Formula 2 is a compound of Formula 2b:Formula 2b.

16. The process of any one of claims 1 to 15, further comprising preparing a compound of Formula 2 via an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:Formula 3 Formula 4 Formula 2;whereinR1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl;X1is a halogen; andX2is a halogen.

17. The process of claim 16, wherein R1is -H.

18. The process of claim 16 or claim 17, wherein X1is chlorine and X2is chlorine.

19. The process of any one of claims 16 to 18, wherein the dihalide compound of Formula 4 is provided in a molar equivalent amount of between about 0.1 and 20, between about 1.0 and 10, between about 1.1 and 5, or between about 1.2 and 1.7, relative to the molar amount of the compound of Formula 3.

20. The process of any one of claims 16 to 19, wherein the N-acylation reaction is performed in the presence of a base reagent.

21. The process of claim 20, wherein the base reagent is potassium carbonate (K2CO3).

22. The process of claim 21, wherein the potassium carbonate (K2CO3) is provided as an aqueous solution.

23. The process of claim 21 or claim 22, wherein the aqueous potassium carbonate solution has a concentration of between about 0.5 M and 10 M, between about 1.0 M and 5.0 M, or between about 1.5 M and 2.5 M.

24. The process of any one of claims 21 to 23, wherein the potassium carbonate (K2CO3) is provided in a molar equivalent amount of between about 0.5 and 5.0, between about 0.75 and 4.0, or between about 1.0 and 3.0, relative to the molar amount of the compound of Formula 3.

25. The process of any one of claims 16 to 24, wherein the N-acylation reaction is performedin the presence of a chlorinated hydrocarbon solvent, an ether solvent, or a combination thereof.

26. The process of claim 25, wherein the organic solvent is dichloromethane (DCM).

27. The process of claim 25, wherein the organic solvent is 2 -methyltetrahydrofuran (2-MeTHF).

28. The process of any one of claims 16 to 27, wherein a reaction mixture comprising a compound of Formula 3 is initially cooled to between about -30 °C to 10 °C, between about -20 °C to 10 °C, or between about -10 °C to 10 °C, immediately prior to the reaction with a dihalide compound of Formula 4.

29. The process of any one of claims 16 to 28, wherein a reaction mixture comprising a compound of Formula 3 and a dihalide compound of Formula 4 is allowed to warm to between about 10 °C and 50 °C, between about 15 °C and 40 °C, between about 15 °C and 30 °C, or between about 15 °C and 25 °C, where the temperature is maintained until completion of the reaction.

30. The process of any one of claims 16 to 29, wherein the N-acylation reaction provides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% conversion of the compound of Formula 3 to the compound of Formula 2.

31. The process of claim 16, wherein the compound of Formula 3 is a compound of Formula 3a:Formula 3a.

32. The process of any one of claims 1 to 31, wherein the bicyclic glycine -proline compound of Formula 1 is a bicyclic glycine -proline compound of Formula 1(7?):Formula 1(R).

33. A bicyclic glycine-proline compound of Formula la:Formula la;prepared by the process of any one of claims 1 to 31.

34. A process for preparing a compound of Formula 2, comprising an N-acylation reaction of a compound of Formula 3 with a dihalide compound of Formula 4:Formula 3 Formula 4 Formula 2;whereinR1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl;X1is a halogen; andX2is a halogen.

35. The process of claim 34, wherein the compound of Formula 3 is a compound of Formula 3a:Formula 3a.

36. The process of claim 34 or claim 35, further comprising reacting a compound of Formula 2 to form the compound of Formula 1:Formula 2 Formula 1;whereinR1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OCi-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8arylis optionally substituted with -OCi-4alkyl; andX1is a halogen.

37. The process of claim 36, wherein R1is -H.

38. The process of any one of claims 36 to 37, wherein X1is chlorine.

39. A composition comprising a bicyclic glycine -proline compound of Formula la:Formula la;and one or more excipients, wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 1) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, or 0.0001.

40. A composition comprising a bicyclic glycine -proline compound of Formula la:Formula la;and one or more excipients, wherein the composition is substantially free of impurities.

41. A composition comprising a compound of Formula 2b:Formula 2b;wherein any impurities, if present, are in an amount (weight % of the amount of the compound of Formula 2b) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

42. A composition comprising a compound of Formula la:Formula la;wherein a compound of Formula 2:Formula 2;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein R1is selected from the group consisting of -H, -Ci-ealkyl, -Ci-ealkyl-C3-8aryl, -C3-8aryl, -C(O)OC1-6alkyl, -C(O)Ci-6alkyl, and -Ci-6alkyl-C(O)-Ci-6alkyl; wherein -C3-8aryl is optionally substituted with -OCi-4alkyl; and X1is a halogen.

43. A composition comprising a compound of Formula la:Formula la;wherein a compound of Formula 2a':Formula 2a';if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001; wherein X1is a halogen.

44. A composition comprising a compound of Formula la:Formula la;wherein Impurity g:Impurity g;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

45. A composition comprising a compound of Formula la:Formula la;wherein Impurity h:Impurity h;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

46. A composition comprising a compound of Formula la:Formula la;wherein Impurity i:Impurity i;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

47. A composition comprising a compound of Formula la:Formula la;wherein Impurity j:Impurity j;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

48. A composition comprising a compound of Formula la:Formula la;wherein Impurity k:Impurity k;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

49. A composition comprising a compound of Formula la(7?):Formula la( / ?);wherein Impurity la(S):Impurity la(S);if present, is in an amount (weight % of the amount of the compound of Formula la(7?)) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

50. A composition comprising a compound of Formula la:Formula la;wherein Impurity a:Impurity a;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

51. A composition comprising a compound of Formula la:Formula la;wherein Impurity b:Impurity b;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

52. A composition comprising a compound of Formula la:Formula la;wherein Impurity c:Impurity c;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.

53. A composition comprising a compound of Formula la according to any embodiments or examples thereof as described herein:Formula la;wherein Impurity d:Impurity d;if present, is in an amount (weight % of the amount of the compound of Formula la) of less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005 or 0.0001.